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                                          ABSTRACT 
Polycystic ovary syndrome (PCOS), diagnosed based on hyperandrogenism, ovulatory 
dysfunction and polycystic ovaries, is one of the most common disorders of reproductive aged 
females affecting up to 18% of women in this age group. The aetiology of PCOS is still 
unknown but includes both genetic and environmental/lifestyle factors contributing to both 
insulin resistance and hyperandrogenism. Clinically PCOS has reproductive, psychological and 
metabolic features, the latter predisposing to cardiovascular disease (CVD). Haemostatic 
abnormalities have an association with and a demonstrated pathophysiological role in CVD in 
non-PCOS populations, yet have not been adequately explored in PCOS. 
 
Women with PCOS appear to have altered coagulation and fibrinolysis with a prothrombotic 
state, with epidemiological evidence of increased venous thromboembolism. In an established 
case-control cohort of lean, overweight and obese women with (n=107) and without (n=67) 
PCOS, and existing measures of plasminogen activator inhibitor 1 (PAI-1) and asymmetric 
dimethylarginine (ADMA), other haemostatic markers were measured in plasma samples 
including prothrombin fragments 1 and 2 (PF1 & 2), plasminogen, tissue plasminogen activator 
(tPA) and thrombin generation (TG). Higher levels of ADMA (0.70 vs 0.39 μmol/L, p<0.01), 
PAI-1 (4.80 vs 3.66 U/mL, p<0.01) and plasminogen (118.39 vs 108.46%, p<0.01) were seen 
in women with PCOS versus controls, which persisted after adjustment for age and body mass 
index (BMI). PF1 & 2 was marginally lower (180.0 vs 236.0 pmol/L, p=0.05), while tPA and 
TG were not different between groups, following adjustment for age and BMI. Significant 
relationships were observed between hormonal and metabolic factors with ADMA and PAI-1. 
Impaired fibrinolysis was demonstrated in PCOS. In the context of abnormal endothelial 
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function, known hormonal and metabolic abnormalities, outcomes of this study suggest there is 
an increased risk of cardiovascular disease and venous thrombosis in women with PCOS.  
 
Women who have PCOS have an increased risk of cardiovascular and venous thromboembolic 
disease (VTE) related to metabolic and hormonal features, obesity and a hypofibrinolytic state, 
and current PCOS treatments may possibly exacerbate these risks. The haemostatic impacts of 
common pharmacological treatments administered to women with the syndrome was 
investigated, and involved a mechanistic sub-study using biobanked samples from a six month 
randomised comparative trial of pharmacological treatments. Pro- and anti-thrombotic markers 
and overall haemostatic activity were measured. Overweight women (mean BMI of 36.5±7.0 
kg/m2) of mean age 33.9±6.7 years with PCOS (n=60) were randomised to either: (1) 
metformin, (2) higher-dose oral contraceptive pill (OCP) or (3) low-dose OCP+spironolactone 
(OCP+S). The main outcome measures included changes over the six month investigation 
period in PAI-1, ADMA, PF1 & 2, plasminogen, tPA, thrombin activatable fibrinolysis 
inhibitor (TAFI) and TG as well as relevant hormonal and metabolic markers. PAI-1 activity 
fell in all groups (p<0.015), ADMA decreased with higher-dose OCP (p=0.0125), PF1 & 2 
increased with metformin and higher-dose OCP (p<0.044), TG increased(p<0.009) and tPA 
decreased in both OCP groups (p<0.013), plasminogen increased in all (p<0.038) and TAFI 
increased after higher-dose OCP (p=0.0004). Endothelial function (marker of the primary 
haemostatic response) improved with higher-dose with some improvement with low-dose 
OCP+S and metformin. Both OCPs however increased coagulation and induced a 
hypofibrinolytic state in the higher-dose form, with a subsequent increased risk of thrombosis. 
Metformin did not show (net) negative effects on overall coagulation. The results suggest an 
additional dimension of treatment (haemostatic system effects) that favours metformin over 
that of OCPs in PCOS. 
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The fibrinolytic system and relevant inhibitors play a number of roles, apart from their function 
in blood haemostasis and thrombosis, namely in ovulation processes. Plasminogen is converted 
to plasmin at the time of follicular rupture through a decrease in PAI-1 and an increase in 
plasminogen activators. Only active plasmin is involved in follicular wall breakdown. PCOS is 
the leading cause of anovulatory infertility with oligo-/anovulation and ovarian follicle arrest as 
key characteristics. The presence and distribution of fibrinolytic/proteolytic markers 
plasminogen, plasminogen/plasmin, tPA and uPA and inhibitor PAI-1 in the ovaries of control 
and PCOS mice were examined using an existing PCOS mouse model with dihydrotestosterone 
treated mice that display extensive ovarian, endocrine and metabolic features of humans 
affected by the syndrome. The expression of PAI-1, tPA, uPA, plasmin/plasminogen and 
plasminogen on six PCOS and six control ovaries were examined by immunohistochemistry 
using the appropriate antibodies and quantitative comparisons using digital image analysis were 
completed. There was a difference in the ovarian distribution of PAI-1 that was localised 
throughout the PCOS ovary unlike a peripheral distribution seen in control ovaries and 
plasminogen that was observed in small follicles only in PCOS and not in small follicles of 
control ovaries. While no differences were noted in the overall expression (mean total 
percentage and mean colour intensity) of ovarian staining of markers assessed, these findings 
showed a potential role for the plasminogen system in both the physiological mouse ovary and 
in the pathological PCOS state. Further studies evaluating these markers at different time-points 
of ovulation will help to further clarify both physiological and potential pathological roles these 
markers play in ovulation processes distorted in PCOS. 
 
Collectively these related studies enhance our understanding of the haemostatic and 
fibrinolytic/proteolytic systems in women with PCOS. As a hypofibrinolytic state was 
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demonstrated in the first study, this serves as a potential further CVD and VTE risk factor in a 
group of women already at high-risk. Additionally, use of the commonly prescribed OCPs in 
the management of women with PCOS has also demonstrated potential further risk factor/s for 
thrombosis following observations of increased coagulation and a hypofibrinolytic state with 
use of the higher-dose form. Metformin however did not show any net negative coagulation 
outcomes and was noted to be the treatment of choice over the use of both OCPs in the 
management of women with this syndrome. While at a systemic level a hypofibrinolytic state 
may increase venous thrombotic risks, the third study showed that at a local ovarian level 
fibrinolytic system changes are also observed in the PCOS ovary in comparison to normal 
ovaries and may be associated with the aberrant ovulation frequently noted in women with 
PCOS. Overall the results from these studies will enhance our understanding of PCOS, help to 
better inform clinical practice as well as assist with development of improved treatment 
options. 
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 CHAPTER 1: General Overview of PCOS 
 
1.1 Preface 
The present chapter provides an overview of the background of the thesis where the 
pathogenesis of the syndrome, clinical presentations, diagnosis and current treatments including 
gaps and controversies in our knowledge, with emphasis on links to cardiovascular disease 
(CVD) and cardiovascular (CV) risk markers frequently present in women with PCOS is 
discussed. I discuss recently published data that suggests an additional clinical complication of 
elevated CV risk in PCOS, potentially relating to disturbed haemostasis. In this context, the 
normal haemostatic system and its functions and the role/s this may play as a potential further 
CVD risk marker are also discussed. Additionally, as PCOS is a primary cause of anovulatory 
infertility in reproductive-age women, the role of specific haemostatic markers (fibrinolytic 
system and relevant inhibitors) in the ovulation process as well as the links these have to 
fertility are introduced. The critical need for an in-depth review of the literature into the 
haemostatic system in women with PCOS is ultimately identified. 
This chapter has been published in Trends in Cardiovascular Medicine (refer to the end of 
Chapter 2 for the original paper). Additional information has been added here in this chapter (as 
well as in Chapter 2) as is relevant to this thesis and to provide more comprehensive and up-to-
date information since this original paper was published. 
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1.2 Introduction and definition of PCOS 
Polycystic ovarian syndrome is a condition diagnosed based on anovulation and irregular 
menstrual cycles, hyperandrogenism and polycystic ultrasound appearance of ovaries (Teede, 
Misso et al. 2011, Sirmans and Pate 2013). PCOS also presents with hypertension and 
metabolic abnormalities, including glucose intolerance, insulin resistance (IR), 
hyperinsulinaemia, and dyslipidaemia, and increased risks for diabetes and CVD (Teede, Misso 
et al. 2011, Sirmans and Pate 2013). The exact cause/s of PCOS remains to be elucidated. It is a 
complex disease believed to be similar to diabetes mellitus, rheumatoid arthritis, and CVD; a 
combination of genetic predisposition and environmental factors contribute to the phenotypic 
expression of this heterogeneous disorder (Teede, Deeks et al. 2010). Occurrence of PCOS 
within families and following high prevalence of the syndrome amongst first-degree relatives 
supports the genetic link to the disorder (Sirmans and Pate 2013). Early research reported on a 
genetic link in PCOS with genes involved in insulin action (glucose metabolism), weight and 
energy regulation, gonadotropin secretion and function and androgen secretion and function 
(Table 1.1). More recent large scale genome wide association studies, reported in a review by 
Azziz, implicated genes involved in neuroendocrine and ovarian androgen synthesis, in 
addition to genes involved in modulation of gonadotropin and insulin function in women with 
the syndrome (Azziz 2016). PCOS is one of the most common disorders of females of 
reproductive age and is the most common endocrine disorder of females in this age group 
around the world (March, Moore et al. 2010, Goodman, Cobin et al. 2015), affecting up to 20% 
of women (March, Moore et al. 2010). It should be noted that the distribution of the disease is 
not restricted to developed nations nor to Caucasian populations (Azziz 2017). Ethnicity as well 
as environmental contributions including obesity modify prevalence rates and severity of the 
condition. In Australian Indigenous women the incidence is as high as 21% (Davis, Knight et 
al. 2002). Furthermore the diagnostic criteria used also impacts reported prevalence rates 
The Haemostatic System in PCOS  
 
10 | P a g e  
 
(Sirmans and Pate 2013). Use of the Rotterdam criteria has noted prevalence rates two to three 
times greater than use of the National Institute of Health (NIH) criteria (Sirmans and Pate 
2013), though the differences noted may be related to the sensitivity of the testing methods 
used to diagnose the syndrome (Azziz, Carmina et al. 2016). Systematic review evidence 
shows more a limited impact of diagnostic criteria on prevalence (Original NIH criteria: 6% 
and Rotterdam criteria: 10%) (Bozdag, Mumusoglu et al. 2016). 
Given its prevalence and significant clinical complications, PCOS presents a major burden to 
its sufferers and the health care system (Teede, Misso et al. 2011). In 2005, based on US data, 
PCOS was estimated to cost the Australian health care system approximately $400 million per 
year (Azziz, Marin et al. 2005). Given the underestimated prevalence from this initial 
evaluation (6%), the actual financial burden is estimated to be significantly higher (Azziz, 
Marin et al. 2005, March, Moore et al. 2010).  
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Table 1.1 Genes considered to play a role in PCOS. 
 
 
Physiological process Genes that may be affected in PCOS 
Gonadotropin secretion activin receptor 1, activin receptor 2A, activin receptor 2B, follicle-
stimulating hormone receptor, follistatin, inhibin subunit A, inhibin 
subunit βA, inhibin subunit βB, inhibin subunit C, luteinizing 
hormone β subunit, luteinizing hormone/choriogonadotropin 
receptor, Müllerian inhibiting substance, sex hormone-binding 
globulin, mothers against DPP homolog 4 
Androgen production & 
secretion 
androgen receptor, bone morphogenic protein, growth 
differentiation factor 9, cytochrome P450, family 11, subfamily A 
polypeptides, cytochrome P450, family 17, subfamily A, 
polypeptide 1, cytochrome P450, family 19, subfamily A, 
polypeptide 1, hydroxyl-δ-5-steroid dehydrogenase, 3β- and steroid 
δ-isomerase 1,hydroxyl-δ-5-steroid dehydrogenase, 3β- and steroid 
δ-isomerase 2, hydroxysteroid (17-β)-dehydrogenase 1, 
hydroxysteroid (17β)-dehydrogenase 2, hydroxysteroid (17β)-
dehydrogenase 3, steroidogenic acute regulator 
Insulin secretion and 
obesity 
adiponectin, calpain 10, insulin gene variable number of tandem 
repeats, insulin receptor, insulin receptor substrate 1, insulin 
receptor substrate 2, insulin-like growth factor 1, insulin-like growth 
factor 2, insulin-like growth factor 1 receptor, insulin-like growth 
factor 2 receptor, insulin-like growth factor binding protein 1 plus 
insulin-like growth factor binding protein 3, peroxisome 
proliferatoractivated receptor γ, Leydig insulin-like protein, leptin 
receptor, leptin, melanocortin-4 receptor, tumor necrosis factor, 
uncoupling protein 2, uncoupling protein 3, propiomelanocortin 
Adapted from(Urbanek 2007). 
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1.3 Pathogenesis 
1.3.1 Hyperandrogenism 
PCOS has a complex pathogenesis with features that ultimately feedback in a chain reaction-
like manner to further aggravate clinical observations. Hyperandrogenism, the predominant 
feature of the syndrome, is primarily of ovarian origin (~60% of cases)(Azziz 2017) with some 
contribution from the adrenal gland (~40% of cases) (Luque-Ramirez and Escobar-Morreale 
2015, Krishnan and Muthusami 2017). Increased luteinizing hormone (LH) activity from the 
pituitary gland and increased LH/FSH levels as well as increased LH response to theca cells in 
polycystic ovaries has been observed in PCOS and is likely involved in the pathogenesis of the 
hormonal imbalance of the disorder (Krishnan and Muthusami 2017). 
1.3.2 Insulin Resistance and Hyperinsulinaemia 
IR, which occurs independently of obesity, is observed in 75% of lean and 95% of obese PCOS 
females (Stepto, Cassar et al. 2013, Teede and Shorakae 2017) and contributes to the 
pathophysiology of this syndrome (Sirmans and Pate 2013, Azziz 2017). Insulin stimulates 
secretion of androgens by the ovarian theca cells (Krishnan and Muthusami 2017). In PCOS, 
these cells appear to be hyper-responsive to insulin in secreting androgens (Azziz 2017). It was 
previously thought that hyperandrogenism may act on vascular tissues to induce an IR state 
(Carmassi, De Negri et al. 2005), however more recent literature is focusing on androgen action 
via the adipocyte tissues as a potential link to IR (Keller, Chazenbalk et al. 2014). IR has also 
been linked with an abnormal lipid profile in PCOS compared to more insulin-sensitive 
controls. This is probably due to excessive hypersecretion of apolipoprotein B and very low-
density lipoprotein (VLDL) from the liver following insulin stimulation, ultimately resulting in 
hypertriglyceridaemia (Alexander, Tangchitnob et al. 2009). Low levels of high-density 
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lipoprotein (HDL) have also been reported in PCOS, as have high levels of low-density 
lipoproteins (LDL) and triglycerides (Berneis, Rizzo et al. 2007, Wild, Rizzo et al. 2011, 
Sirmans and Pate 2013). Insulin-sensitizing agents such as metformin and lifestyle 
interventions that reduce IR have been shown to ameliorate the clinical findings of PCOS 
(Teede, Misso et al. 2011). Additionally insulin sensitisers can reduce dehydroepiandrosterone 
sulfate (DHEAS) androgen levels in some but not all women with PCOS (Luque-Ramirez and 
Escobar-Morreale 2015). In contrast, obesity, which increases IR, exacerbates PCOS (Teede, 
Deeks et al. 2010, Sirmans and Pate 2013). IR and compensatory hyperinsulinaemia however 
are insufficient for development of the disorder (Azziz 2017) and the presence of the syndrome 
in insulin-sensitive PCOS females may indicate further/other causative factor/s or an 
underlying aetiology in the pathogenesis of the syndrome. 
1.3.3 Disturbed Oestrous Cycle and Polycystic Ovaries (PCO) 
In healthy women not affected by the syndrome, the menstrual cycle is initiated by the pituitary 
gland, following stimulation by the hypothalamic gonadotropic releasing hormone (GnRH), 
secreting LH. This in turn stimulates the ovarian theca cells to increase their production of 
androgens (testosterone, androstenedione and DHEAS). Pituitary gland secretion of FSH, also 
following stimulation by GnRH, ensures aromatization of the androgens to oestrogens by the 
ovarian granulosa cells (Azziz 2017). LH production also induces the maturation and growth of 
the ovarian follicles (composed of theca and granulosa cells and enveloped in an outer capsule). 
The follicles, in the early stage of the oestrous cycle, start as small primordial follicles, then 
grow in size to develop into primary and then secondary follicles and finally form the mature or 
Graafian follicles. An LH surge mid-cycle assists in the ovulation process by arrest and rupture 
of the mature ovarian follicles with subsequent release of the oocyte (Figures 1.1 and 1.2). 
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Figure 1.1 The physiological ovulation process (taken from 
https://www.ovulationcalculator.com/img/uploads/2016/01/ovulation-hormones.png Last 
Accessed 21/11/2017). 
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Figure 1.2 Physiological development of ovarian follicles, showing the theca cell layers on the 
external surface and granulosa cell layers as the inner layers of developing follicles (adapted 
fromwd.edu.tw/~cwlou/projects.html Last accessed 13/12/2017). 
 
The normal ovary is a small, walnut sized tissue that is of smooth appearance in girls prior to 
menstruation. As a woman begins to ovulate, the ovary will display a number of protrusions on 
the surface that will vary in size depending on the stages of the menstrual cycle (Figure 1.3). 
These are formed as a result of follicular maturation and once a size of 10-12mm in diameter is 
reached in the mature follicle, follicular wall rupture takes place, which is then replaced by the 
corpus luteum (Figure 1.2). Other developing follicles in that cycle then undergo atresia. 
Progesterone is then produced by the corpus luteum however if pregnancy is not achieved these 
levels fall, menstruation occurs and a new cycle commences. 
In women affected by PCOS the normal menstrual cycle is disturbed. Relatively elevated LH 
levels induce excessive androgen production by the ovarian theca cells as well as a failed 
Granulosa cells in 
developing follicles 
Theca cells in 
developing follicles 
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ovulation process following a lack of full ovarian follicular maturation and rupture. Arrested 
follicles in various stages of maturation (atresia), ranging from small or pre-antral follicles to 
more mature or secondary (antral) follicles are noted in women with PCOS due to excessive 
LH stimulation (elevated LH level as well as pulse frequency) (Krishnan and Muthusami 
2017). The ovary then appears enlarged (up to three times the size of a normal ovary) with 
multiple (>10–12) underdeveloped follicles (~2–9 mm in diameter) on the surface and a 
thickened capsule (Figure 1.3). Therefore the inclusion of ‘polycystic’ within the name of the 
syndrome is an inaccurate representation of its features; these are not cysts but rather 
underdeveloped follicles. 
 
 
Figure 1.3 Polycystic (left) versus normal (right) ovary. 
 
1.3.4 Obesity  
Women affected by PCOS are more likely to be overweight, obese and display central obesity 
than those who are not, and the incidence and severity of this syndrome increases with 
increased weight (Teede, Misso et al. 2011, Lim, Davies et al. 2012, Behboudi-Gandevani, 
Ramezani Tehrani et al. 2017). Obesity exacerbates both IR and hyperandrogenism. 
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Additionally central obesity is a risk factor for development of IR as well as a main component 
of the metabolic syndrome (Behboudi-Gandevani, Ramezani Tehrani et al. 2017). Although 
some studies have found abnormal fasting insulin levels and IR only in obese PCOS females 
(Rajendran, Willoughby et al. 2009), most studies have also observed these abnormal metabolic 
profiles in lean counterparts (Dereli, Ozgen et al. 2003, Ozgurtas, Oktenli et al. 2008).        
Two-thirds of studied non-obese PCOS females are reported to have excessive body fat and 
central visceral adiposity inducing greater IR (Cascella, Palomba et al. 2008). Excess adipose 
tissue also ensures increased extraglandular aromatization of androgens into oestrogens 
resulting in a feedback loop on the hypothalamus which then increases LH and subsequent 
androgen production. It is not clear as yet whether excessive weight gain is an aetiological 
factor or symptom of the syndrome however it appears to be bidirectional (Teede, Joham et al. 
2013). 
 
1.4 Clinical and Diagnostic Features 
Clinical manifestations of PCOS are highly variable and may include reproductive, metabolic, 
as well as psychological features. When fully expressed, features of PCOS may include 
hirsutism, acne and/or alopecia, menstrual irregularities, sub-fertility and pregnancy 
complications including miscarriage and gestational diabetes, obesity, increased risks of Type 2 
diabetes (4-7 fold) and potentially cardiovascular disease (Rosenfield 2009); increased 
psychological features including depression and anxiety (Lobo, Granger et al. 1983, Deeks, 
Gibson-Helm et al. 2010) and increased risks of various cancer types such as endometrial 
carcinoma. PCOS symptoms however can be restricted to only a few of these features, making 
both diagnosis and treatment a significant challenge (Teede and Shorakae 2017).  
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Common reproductive abnormalities include oligo or amenorrhoea and infertility. PCOS 
women that are successful in conceiving are then faced with increased risks of pregnancy 
associated complications including pre-eclampsia, gestational diabetes and early delivery 
(Teede and Shorakae 2017).    
While reproductive abnormalities predominate in younger women with the syndrome, 
metabolic features have also been noted as key characteristic and are independent of weight, 
though a high body mass index (BMI) will increase these risks (Teede and Shorakae 2017). 
The incidence of metabolic syndrome is also increased in women with PCOS (Sirmans and 
Pate 2013). Other metabolic aberrations include glucose intolerance and increased risks of   
pre-diabetes, gestational diabetes and type 2 diabetes, dyslipidaemia and obstructive sleep 
apnoea (Teede and Shorakae 2017), many of which predispose to and are well known risk 
factors for CVD. 
Psychological abnormalities include depression, anxiety, eating disorders, psychosexual 
dysfunction and reduced self-esteem, that can be related to but may also occur independent of 
obesity and reduce the quality of life of women with the syndrome (Teede and Shorakae 2017). 
A summary of the aetiology and clinical features of PCOS is represented in Figure 1.4 (Teede, 
Misso et al. 2011, Goodman, Cobin et al. 2015, Teede and Shorakae 2017). 
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Figure 1.4 Summary of the aetiology and clinical features of PCOS (adapted from Teede, 
Misso et al. 2011). 
 
The initial diagnostic criteria from 1990 by the NIH incorporated the presence of polycystic 
ovaries as a main diagnostic component in conjunction with hyperandrogenism, made 
following clinical (hirsutism or acne) or biochemical (elevated androgen levels, mainly 
testosterone) evaluation and abnormal ovulation, demonstrated through oligo or anovulation  
(6-9 or fewer menstrual cycles per year or abnormal bleeding) following exclusion of other 
causes of hyperandrogenism or menstrual irregularities (such as congenital adrenal hyperplasia, 
androgen secreting tumours and hyperprolactaemia) (Zawadski and Dunaif 1992). In 2003, the 
diagnostic criteria was revised by the European Society of Human Reproduction and 
Embryology (ESHRE) in conjunction with the American Society of Reproductive Medicine 
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(ASRM) or the so called “Rotterdam criteria” that expanded to include ultrasound features of 
PCOS (Rotterdam 2004). Diagnosis then required two of three core clinical manifestations: 
hyperandrogenism, anovulation and PCO on ultrasound, in addition to exclusion of other 
related disorders (Table 1.2).  
Table 1.2 Various diagnostic criteria used for defining PCOS (Zawadski and Dunaif 1992, 
Rotterdam 2004, Azziz, Carmina et al. 1996). 
 
Reference Criteria 
NIH 1990 To include all of the following and exclude related disorders: 
x Clinical hyperandrogenism and/or hyperandrogenaemia 
x Chronic anovulation 
x Polycystic ovaries 
ESHRE/ASRM 
(Rotterdam) 
2003 
To include two of the following, in addition to exclusion of related 
disorders: 
x Oligo-anovulation 
x Hyperandrogenism and/or hyperandrogenaemia 
x Polycystic ovaries 
AES 2006 To include all of the following: 
x Hyperandrogenism (hirsutism and/or hyperandrogenaemia) 
x Ovarian dysfunction (oligo-anovulation and/or polycystic ovaries) 
x Exclusion of related disorders 
 
Both the original NIH as well as the Rotterdam criteria however received criticism. The 
diagnosis of hyperandrogenism could be made both clinically as well as biochemically. The 
clinical manifestation of hyperandrogenism can vary significantly between individuals and 
therefore some argued that only laboratory evaluation of hyperandrogenism should have been 
used (Rosenfield 2009, Barbieri and Ehrmann 2017). The introduction of two out of the three 
clinical symptoms in the Rotterdam criteria made by ESHRE/ASRM also meant that women 
presenting with polycystic ovaries and abnormal ovulation would be diagnosed as having 
PCOS, despite no hyperandrogenism. Women could also have PCOS and be asymptomatic 
with PCO on ultrasound and having biochemical hyperandrogenism, although this scenario was 
uncommon as women are not presenting with a clinical problem. These were then argued as 
The Haemostatic System in PCOS  
 
21 | P a g e  
 
inappropriate inclusions and it was contested that hyperandrogenism must be present in order 
for diagnosis to be made (Rosenfield 2009). One of the recommendations why non-hirsute 
women with PCO and normal circulating androgens should still be considered as having PCOS 
is due to the non-accurate commercial kits for determining androgen levels (Rosner 2001, 
Goodman, Cobin et al. 2015). These diagnostic shortcomings then made way for the Androgen 
Excess Society (AES) to introduce a further diagnostic criterion in 2006.  These suggested that 
PCOS is a condition presenting with mandatory androgen excess (clinical and/or biochemical) 
plus one of ovarian dysfunction (oligo-anovulation and/or polycystic ovarian morphology) and 
exclusion of other androgen excess or ovulatory disorders (Azziz, Carmina et al. 2006). While 
the name Polycystic Ovarian Syndrome persists, this clinical feature is not mandatory for 
diagnosis in the AES criteria (Azziz, Carmina et al. 2006). The AES recommendation may also 
fall short, in that it too accepts the inclusion of clinical not just biochemical diagnosis of the 
syndrome. Furthermore, due to the high prevalence of the symptoms in PCOS, it is likely that 
obesity and IR should also be incorporated when diagnosis is made. 
At present up to 70% of women with PCOS remain undiagnosed due to the heterogeneity of the 
syndrome (Teede and Shorakae 2017). In 2012 an Expert Panel from a NIH Evidence Based 
Methodology Workshop on PCOS, reinforced the use of the wider Rotterdam criteria (NIH 
Disease Prevention Evidence-based Methodology Workshop on PCOS 2012). This criteria, 
based on the presence of only two of the following three clinical features: hyperandrogenism 
(clinical or biochemical), chronic anovulation and polycystic ovaries on ultrasound remains the 
most widely accepted and used diagnostic criteria by clinicians internationally.  
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1.5 Treatment 
The current management strategies use to ameliorate the symptoms of PCOS are highly 
variable, in line with the diverse range of clinical features of the syndrome (Table 1.3) (Teede, 
Misso et al. 2011, Goodman, Cobin et al. 2015). Conventionally most treatments have targeted 
only the symptoms but not focused on prevention of long-term complications and have not 
recognised the important role of lifestyle change, metabolic and psychosocial impacts of PCOS. 
At present women with PCOS display reduced satisfaction with the care and management 
provided by health professionals and are often diagnosed late (Teede and Shorakae 2017). 
Current approaches should comprise an initial thorough evaluation of each woman affected by 
the syndrome as well as incorporate a multidisciplinary approach to treatment to ensure the 
most appropriate management strategy is tailored. These should also seek to address all features 
of the syndrome including reproductive but also metabolic and psychological characteristics 
and focus on  prevention of long-term complications including the increased risks of CVD 
(Teede and Shorakae 2017). 
 
Table 1.3 Management therapies used to treat women with PCOS (Teede, Misso et al. 2011, 
Teede and Shorakae 2017). 
Clinical feature/complication Management strategy 
Oligomenorrhoea/ 
amenorrhoea 
Lifestyle change (5%–10% weight loss + structured exercise) 
Oral contraceptive pill (OCP) (low oestrogen doses [eg, 20 μg] may 
have less impact on IR, though more evidence is needed to confirm 
this) 
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Cyclic progestins (eg, 10 mg medroxyprogesterone acetate 10–14 
days every 2–3 months) 
Metformin (improves ovulation and menstrual cyclicity) 
Hirsutism Choice of options depends on patient preferences; impact on 
wellbeing; and access and affordability: 
Self-administered and professional cosmetic therapy are first line 
(laser recommended) 
Eflornithine cream can be added and may induce a more rapid 
response 
If cosmetic therapy is not adequate, pharmacological therapy can be 
considered 
Pharmacological therapy 
•Medical therapy if patient is concerned and cosmetic therapy is 
ineffective/inaccessible/unaffordable 
•Primary therapy is the OCP (monitor glucose tolerance in those at 
risk of diabetes) 
•Anti-androgen monotherapy (eg, spironolactone or cyproterone 
acetate) should not be used without adequate contraception 
•Trial therapies for ≥6 months before changing dose or medication 
•Combination therapy if  ≥6 months of OCP is ineffective, add anti-
androgen to OCP (twice daily spironolactone >50 mg or cyproterone 
acetate 25 mg/day, days 1–10 of OCP) 
Infertility Lifestyle intervention (to optimise preconception health and fertility 
and reduce pregnancy and long-term complications) 
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Clinical features of excess androgen levels are primarily approached with cosmetic treatments. 
They can also be controlled along with menstrual cycle abnormalities using combined 
oestrogen- and progestin-based oral contraceptive pills (OCP) (Teede and Shorakae 2017). 
These also act to protect against endometrial hyperplasia that can develop due to chronic 
anovulation, due to their progestin component (Teede and Shorakae 2017). If hirsutism or 
alopecia are severe, then an anti-androgen drug such as spironolactone or cyproterone acetate 
can be introduced (in combination with oral contraceptives) (Teede and Shorakae 2017). The 
frequently prescribed OCP present with the well-accepted risk of venous thromboembolism. 
This risk is further amplified because many women with PCOS are overweight (Teede, Misso 
et al. 2011). OCP also have a negative effect on blood lipids, blood pressure and may increase 
the risk of insulin resistance (McCartney and Marshall 2016, Teede and Shorakae 2017), 
Advise on folate, smoking cessation and optimal weight and exercise 
before conception 
Given age-related infertility, advise women to optimise family 
initiation 
Infertility therapies may include clomiphene citrate, metformin, 
gonadotropins, surgery and in vitro fertilisation. 
Cardiometabolic risk Lifestyle change: >5% weight loss in those who are overweight 
reduces diabetes risk by approximately 50%–60% in high-risk 
groups 
Optimise cardiovascular risk factors 
Consider metformin (reduces the risk of diabetes by ~50% in 
adherent high-risk groups) 
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increasing metabolic and CVD risk factors. Low-dose OCP are currently recommended to 
reduce some of these risks (Teede and Shorakae 2017). OCP use however is inappropriate for 
women wishing to conceive and those who have side effects. It is not clear if there are any 
specific interactions between OCP and PCOS. Metformin has been shown to reduce 
hyperinsulinaemia (McCartney and Marshall 2016), improve IR and menstrual cycles and 
appears to improve fertility (Teede, Misso et al. 2011). Metformin has been shown to increase 
pregnancy rates but not live birth rates (Legro, Barhart et al. 2007, Tang, Lord et al. 2012). 
Further study is needed to define the role of metformin in PCOS management (Teede, Misso et 
al. 2011).  
For women wishing to conceive, lifestyle intervention including regular exercise and caloric 
restrictions is the first line of treatment (Teede and Shorakae 2017). Ovulation induction can be 
achieved through weight loss (Barbieri and Ehrmann 2016) in women who are overweight. The 
data relating to the use of insulin sensitizing agents such as metformin is inconclusive. 
Metformin can assist in the treatment of metabolic abnormalities as well as menstrual 
irregularities but has limited or no effect in the treatment of infertility (Legro, Arslanian et al. 
2013). Others have noted that overall metformin has a variable effect on ovulation function 
(McCartney and Marshall 2016). A consensus group has advised the use of metformin be 
restricted only to PCOS women with glucose intolerance (Barbieri and Ehrmann 2016). 
Clomiphene, a drug that stimulates the pituitary gland to increase its secretion of FSH, is 
currently first-line treatment for women with PCOS that require ovulation induction (Legro, 
Arslanian et al. 2013). Gonadotropins, aromatase inhibitors and laparoscopic ovarian drilling 
are further possible treatment options in suitable cases for PCOS women requiring assisted 
fertility (Teede and Shorakae 2017). 
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Recently guidelines and recommendations for early and regular screening of women with 
PCOS for detection of metabolic features and complications have been put forth (Teede and 
Shorakae 2017). Screening for glucose intolerance, type 2 diabetes, gestational diabetes (during 
pregnancy), dyslipidaemia, hypertension and obstructive sleep apnoea may help to reduce the 
risks of CVD development these factors attract. It is also recommended to screen women with 
PCOS for other risk factors of CVD including BMI, fatty liver and smoking status.  
It is recommended that women with PCOS be screened for psychological features including 
anxiety and depression which constitute the most common mood disorders. Treatment options 
are varied however and it is important to consider management of weight gain and treatment of 
hirsutism to help improve the quality of life of women affected by this syndrome (Teede and 
Shorakae 2017).  
In summary, despite significant developments in the treatment of women with PCOS over the 
last few years, areas of controversy still remain and further research is still needed. 
 
1.6 The haemostatic system under a physiological state  
The structure and function of the haemostatic system and its components under physiological 
state have been described here in order to provide the necessary background information and 
for improved understanding of the system’s role and links to CVD and VTE as well as to 
provide for clearer comprehension of the methodology/ies used in several of the studies 
completed. 
The haemostatic system functions to keep blood in a fluid state within the vasculature and 
ensure adequate supply of oxygen and nutrients to tissues. It also assists to prevent blood loss 
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when blood vessel injury occurs through the formation of a stable blood clot or thrombus at the 
site of damage. It is composed of four major systems or responses, including the primary and 
secondary haemostatic systems, the fibrinolytic system and coagulation inhibitors as well as 
inhibitors of fibrinolysis, as discussed below.  
1.6.1 The primary haemostatic system 
The primary haemostatic system/response predominantly includes the vasculature and platelets. 
The endothelial cell lining, as the inner most layer of blood vessels, plays a critical role in 
blood haemostasis, which under a normal physiological state and when intact, releases nitric 
oxide (NO), that inhibits vascular smooth muscle contraction and growth as well as preventing  
platelet aggregation, allowing adequate flow of blood through the vessel lumen to reach the 
tissues (Turgeon 2017). Prostacyclin, also secreted by intact endothelial cells, acts to inhibit 
platelet adhesion and aggregation (Turgeon 2017). The basement membrane acts to support the 
endothelial cell layer and is known as the sub-endothelium. This is composed of collagen and is 
highly thrombogenic, ensuring platelet activation and initiation of thrombosis when exposed. 
The endothelium and sub-endothelium are surrounded by a layer of smooth muscle and elastic 
fibres (tunica media) and finally the outermost layer of blood vessels (tunica externa) is 
composed of fibrous connective tissue (Turgeon 2017).  
Following blood vessel injury vasoconstriction ensures to reduce loss of blood from the 
vasculature (Hoffbrand, Moss et al. 2006). Damage to endothelial cells exposes the 
thrombogenic sub-endothelium and activation of platelets ensures. Platelets then adhere to the 
collagen in the subendothelial connective tissue (either directly or through the ‘bridge’ 
molecule von Willebrand factor), change shape, from a disc to a sphere with pseudopods to 
increase their surface area, and release their contents (Turgeon 2017). Platelets are composed of 
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a plasma membrane surrounded by a glycocalyx containing various glycoproteins (GP) 
including GPIb and GPIIb/IIIa that assist in platelet adhesion (to damaged blood vessel walls) 
and aggregation (platelet adhesion to each other) processes (Turgeon 2017). Platelets are 
composed of three major storage components related to haemostasis: alpha granules, dense 
granules (bodies) and lysosomes. Alpha granules include fibrinogen, factor V and factor VIII as 
factors part of the coagulation cascade (described later) have a predominant pro-coagulant 
effect (Turgeon 2017). Dense granules include ADP and ATP that assist in platelet activation 
and aggregation, calcium which is required at various stage in the coagulation cascade and 
serotonin which can assists in vasoconstriction (Turgeon 2017). Lysosomes contain several 
hydrolytic enzymes. Following platelet adhesion to the damaged blood vessel wall and release 
of platelet contents, a chain reaction of events ensures whereby each platelet, upon adhesion to 
the blood vessel wall or other platelets, releases its granules and causes further platelet 
recruitment, adhesion and aggregation, ultimately resulting in the formation of a primary 
platelet thrombus (Hoffbrand, Moss et al. 2006, Turgeon 2017). This is then further stabilised 
through the activation of the coagulation cascade, also known as the secondary haemostatic 
system/response.  
1.6.2 The coagulation system 
In vitro the coagulation cascade exerts its effects through the extrinsic pathway (activated by 
tissue factors including thromboplastin released from damaged tissue cells) and the intrinsic 
pathway (activated by exposed collagen or platelet phospholipid) (Figure 1.5) with further 
potential interactions observed in current in vivo coagulation cascade concepts (Figure 1.6), 
which also recognise the importance of cellular (surfaces) interactions with coagulation 
proteins. The coagulation cascade factors (denoted mainly by Roman numerals) are composed 
predominantly of serine proteases and their cofactors, which, through proteolytic activation, act 
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to transform downstream enzymes from their inactive to active forms (denoted by inclusion of 
subscript ‘a’ next to each Roman numeral number) and ultimately result in the conversion of 
soluble fibrinogen into insoluble fibrin by the action of thrombin (Turgeon 2012). Thrombin is 
also able to cause further coagulation cascade amplification by activation of coagulation 
cascade factors V, VIII and XI. Thrombin is also a powerful platelet activator and able to 
stimulate further platelet activation and aggregation steps (Turgeon 2017). Conversely 
thrombin can also act as a coagulation inhibitor following attachment to antithrombin (AT) that 
ultimately inhibits its action, stimulates endothelial cell release of plasminogen activators as 
well as attaching to thrombomodulin which then results in the inactivation of factors Va and 
VIIIa (Turgeon 2017). Thrombin activation of coagulation factor XIII results in formation of 
cross-linked fibrin polymers. Ultimately in the coagulation cascade, cross-linked fibrin acts to 
enmesh the initial primary platelet thrombus into a more stable form and further reduce the loss 
of blood (Figure 1.5) (Hoffbrand, Moss et al. 2006, Turgeon 2012, Turgeon 2017).  
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Figure 1.5 The ‘classical’ in vitro coagulation cascade. Coagulation is activated through both 
the intrinsic pathway which involves contact activation factors prekallikrein (PK), high 
molecular weight kininogen (HMWK) and factors XII and XI while the extrinsic pathway 
follows from release of tissue thromboplastin (T. Thromboplastin) from damaged tissues to 
ultimately converge at a common pathway (following activation of factor X to Xa) and convert 
insoluble fibrinogen into fibrin (cross-linked) to enmesh the initial platelet thrombus formed 
into a much more stable form. PK, prekallikrein; HMWK, high molecular weight kininogen; 
Kall., Kallikrein; T. Thromboplastin, tissue thromboplastin; PF3, platelet factor 3 (adapted 
from Turgeon 2017). 
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Figure 1.6 The current ‘in vivo’ (cell-based) coagulation is thought to occur in three stages: 
initiation, amplification and propagation. In the initiation stage a tissue factor (TF) bearing cell 
such as a monocyte presents TF to factor VII which then can activate factors X and IX. 
Activated factor X (Xa) is then able to activate thrombin (or factor IIa) from prothrombin 
(factor II). Thrombin is then able to activate platelets and co-factors V and VIII. The 
amplification stage may then commence whereby the platelet surface acts to provide the 
phospholipid necessary for activated factors VIIIa and IXa and allows for further thrombin 
formation to ultimately generate large amounts of thrombin. Finally in the propagation and 
final stage of the cell based coagulation concept a large volume of thrombin has been generated 
on the platelet surface to ultimately allow for the formation of a large fibrin thrombus. TF, 
tissue factor; PLT, platelet/s (adapted from Turgeon 2017). 
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1.6.3 The fibrinolytic system 
The thrombus is ultimately digested through another system known as fibrinolysis as collagen 
is deposited at the site of injury to seal the damaged area. The fibrinolytic system also acts to 
break down thrombi that have formed inappropriately due to abnormal activation of blood 
coagulation within the blood vasculature and ensures that blood is maintained within its fluid 
form. Tissue plasminogen activator (tPA), one of the principal fibrinolytic system components, 
acts to convert fibrinolytic pro-enzyme plasminogen into active plasmin. Plasmin is able to 
digest fibrinogen, fibrin as well as hydrolise coagulation factors V, VIII and XII (Turgeon 
2017). Plasmin is further able to activate the complement cascade (Turgeon 2017). Other 
activators of plasminogen include the ‘kinases’ urokinase plasminogen activators (uPA), 
streptokinase, staphylokinase but also thrombin (Turgeon 2017). Ultimately plasmin acts to 
break down the thrombus formed releasing fibrin and fibrinogen degradation products 
(Hoffbrand, Moss et al. 2006). These degradation products of split fibrin can exert an 
antithrombin effect as well as inhibit formation of fibrin polymers and platelet aggregation 
(Turgeon 2017). 
1.6.4 Inhibitors of coagulation  
Inhibitors of the coagulation cascade including AT, protein C and cofactor protein S as well as 
tissue factor pathway inhibitor (TFPI) act to control coagulation and prevent aberrant growth of 
the thrombus beyond needs to prevent loss of blood. Continued release of NO and prostacyclin 
by intact endothelial cells surrounding the mechanically damaged tissue also prevents growth 
of the thrombus beyond requirements (Turgeon 2017). Antithrombin (formerly known as 
Antithrombin III), is a glycoprotein that inactivates procoagulant factors thrombin and activated 
factor X (Harper 2017). As a serine protease inhibitor and as indicated earlier AT acts to inhibit 
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plasmin, however it does this to a lesser extent than its negative effects on the procoagulant 
system, resulting in a net anticoagulant effect. This is demonstrated following observations of 
increased risk of both arterial as well as venous thrombosis in patients deficient for AT (Harper 
2017). Protein C, once converted to functional form, activated protein C (APC) following 
attachment to and activation by endothelial-cell associated cofactor thrombomodulin, plays a 
critical role in the anticoagulant pathway. APC, in the presence of cofactor Protein S, is able to 
dramatically reduce the conversion of prothrombin to thrombin by proteolytic cleavage of 
factors Va and VIIIa. APC is also able to break-down inhibitors of tPA and therefore promote 
fibrinolysis (Turgeon 2017).  
1.6.5 Inhibitors of fibrinolysis  
Inhibitors of the fibrinolytic system including plasminogen activator inhibitor-1 (PAI-1), α2 
antiplasmin, α2 macroglobulin and thrombin activatable fibrinolysis inhibitor (TAFI), act to 
control fibrinolysis (Hoffbrand, Moss et al. 2006). PAI-1 is a primary inhibitor of serine 
proteases and fibrinolytic activators tPA and uPA and is secreted predominantly by endothelial 
cells but also adipose tissue and liver hepatocytes. PAI-1 is able to down regulate fibrinolysis 
by preventing cleavage of pro-enzyme plasminogen by serine proteases to active protease 
plasmin (Yasar Yildiz, Kuru et al. 2014). TAFI, secreted mainly by the liver, cleaves lysine 
residues from partially degraded fibrin preventing binding and conversion of plasminogen into 
active plasmin (Karakurt, Gumus et al. 2008).α2 antiplasmin inhibits active plasmin by binding 
to and forming complexes with the latter inhibiting its function. Plasmin in fluid phase (plasma) 
is rapidly converted to plasmin-α2antiplasmin or neutralized by α2 macroglobulin (Syrovets 
and Simmet 2004, Syrovets, Lunov et al. 2012).α2 antiplasmin is present in the plasma at high 
enough concentrations to immediately neutralize up to 50% of available plasmin (Syrovets and 
Simmet 2004, Syrovets, Lunov et al. 2012). The remainder of the 50% is neutralized by α2 
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macroglobulin. Plasmin cannot normally be found in blood as it is inactivated by excess 
presence of inhibitors (Turgeon 2017).   
Overall the haemostatic system is a highly interwoven and complex system (Figure 1.7). 
Although markers of haemostasis have been attributed predominantly pro-coagulant or 
anticoagulant roles, a number of factors can, either directly or indirectly, exert both roles and 
while initially having one predominant action, will have downstream effects within the 
haemostatic system (and other systems) that activate markers to counteract initial effects or 
further propagate these actions. It is therefore critical that any assessment on the haemostatic 
system include a thorough evaluation of all relevant components within this system but also 
incorporate global markers of assessment. 
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Figure 1.7 The systems that ensure balanced Haemostasis: primary haemostasis including 
vascular endothelium and supporting tissues as well as platelets (not shown); secondary 
α2 
Macroglobulin 
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haemostasis that includes the coagulation cascade factors; inhibitors of coagulation including 
antithrombin (AT), protein C (and active form activated protein C, APC) and co-factor protein 
S, tissue factor pathway inhibitor (TFPI) and thrombomodulin (TM); the fibrinolytic system 
including plasminogen and active plasmin, tissue plasminogen activator (tPA), urokinase 
plasminogen activator (uPA) and lastly inhibitors of fibrinolysis including plasminogen 
activator inhibitor 1 (PAI-1), α2 antiplasmin and α2 macroglobulin. HMW, High molecular 
weight; XL-FDP, cross-linked fibrin degradation products (adapted 
fromhttp://diapharma.com/coagulation/ Last accessed 19/12/2017; Note that for clarity and ease 
of understanding not all haemostatic factors have been included in this figure). 
 
1.7 PCOS, CVD and Haemostasis 
PCOS is underpinned by genetic IR, environmental IR (obesity related), as well as metabolic 
abnormalities in the majority of cases (Teede, Misso et al. 2011, Sirmans and Pate 2013). 
Women with PCOS also have evidence of subclinical CVD (Teede, Misso et al. 2011, Zhao, 
Zhu et al. 2016) and appear to have an increased risk of CV events and death (Teede, Misso et 
al. 2011, Hart and Doherty 2015, Azziz, Carmina et al. 2016) especially when combined with 
other risk factors, such as obesity and hypertension (Wild, Carmina et al. 2010), although 
overall evidence is still unclear (Goodman, Cobin et al. 2015, Azziz, Carmina et al. 2016). The 
incidence of metabolic syndrome is increased in both lean and obese females with PCOS 
(Alexander, Tangchitnob et al. 2009, Moran, Misso et al. 2010, Sirmans and Pate 2013). 
Between 30-40% of women with PCOS have impaired glucose tolerance and diabetes, a major 
CV risk factor, is increased fourfold in this patient group (Moran, Brinkworth et al. 2006, 
Sirmans and Pate 2013). Other features associated with metabolic syndrome may occur in 
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PCOS, including a proinflammatory (Shorakae, Teede et al. 2015) and prothrombotic state, 
both of which have well-accepted links to CVD (Alexander, Tangchitnob et al. 2009).  
The underlying mechanism/s of increased cardiometabolic risk in PCOS is/are unclear. 
Although IR is clearly a candidate, studies have shown that both obese and lean women with 
PCOS, both hyperinsulinaemic and those with ambient insulin levels, have increased CVD risk 
(Macut, Micic et al. 2001, Health 2017). Hyperandrogenaemia (with IR) is also linked with 
increased metabolic and CV morbidity in PCOS (Charitidou, Farmakiotis et al. 2008) and high 
androgens and low SHBG levels are associated with increased CVD risk factors in both pre- 
and post-menopausal PCOS females (Health 2011). An elevated testosterone level has also 
been shown to be an independent risk factor for myocardial infarct (MI) and coronary 
atherosclerosis (Kebapcilar, Taner et al. 2009). Others have reported contrary findings 
indicating either a neutral or a beneficial effect of androgens on the vasculature (Worboys, 
Kotsopoulos et al. 2001, Heutling, Schulz et al. 2008). There have also been reports of 
increased inflammatory markers in PCOS, including C-reactive protein (Boulman, Levy et al. 
2004, Health 2017), and of endothelial dysfunction, arterial stiffness, and early atherosclerosis 
as surrogate indicators of CV damage (Moran, Hutchison et al. 2009, Health 2011, Teede, 
Misso et al. 2011). A large number of PCOS females are obese or have excess weight that can 
both directly and indirectly increase CV risk, with increased IR, hyperandrogenaemia, 
dyslipidaemia, and potential activation of the haemostatic system (Teede, Misso et al. 2011, 
Azziz 2017). 
Further research is needed, but OCP may also place women with PCOS at an increased risk of 
developing CV problems through increased risk of arterial thrombotic events, arterial 
dysfunction (Meyer, McGrath et al. 2007), altered glucose metabolism and IR (Meyer, 
McGrath et al. 2007, Charitidou, Farmakiotis et al. 2008), which may increase the risk of type 2 
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diabetes. Women with PCOS taking OCP are also at increased risks of VTE (Bird, Hartzema et 
al. 2013), risks that are well accepted for those in the general population taking the hormonal 
therapy.  
Potentially disturbed haemostasis may also underpin cardiometabolic abnormalities in PCOS. 
Although no epidemiological studies to date demonstrate a clinically evident increased venous 
thrombotic risk, epidemiological studies in PCOS are limited. It was found that 29% of PCOS 
females have a positive family history of venous thrombosis compared to 8% of controls 
(Atiomo, Fox et al. 2000). Shaw et al observed that the incidence of CVD was elevated in 
PCOS females compared to controls (Shaw, Bairey Merz et al. 2008). Although still 
contentious, recent large scale studies have shown that women with PCOS have increased rates 
of both CVD and VTE in comparison to controls (Bird, Hartzema et al. 2013, Hart and Doherty 
2015). Arterial thrombi are the usual cause of strokes and MI, and disturbed haemostasis may 
contribute to CVD risk in PCOS. The haemostatic system is also integrally linked to the 
endothelium and vessel wall. Demonstrated endothelial dysfunction and vessel wall functional 
and structural abnormalities seen in PCOS may also be linked pathophysiologically to disturbed 
haemostasis in PCOS (Moran, Hutchison et al. 2009). Ultimately, a greater understanding of 
the potential pathophysiological role that haemostatic factors play in the cardiometabolic 
features may make way for novel therapeutic measures in PCOS. This is particularly important 
because women are becoming increasingly obese, living longer, and experiencing higher rates 
of diabetes and because CVD is the leading cause of death in women in Australia (Oral, Mermi 
et al. 2009, Health 2011). 
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1.8 Ovulation, fertility and pregnancy outcomes in PCOS and links to fibrinolytic 
system markers 
An excess androgen level in addition to a lack of ovulation has seen PCOS develop into a 
primary cause of infertility, with ~ 75% of women who have anovulation also being affected by 
PCOS (Homburg 2003, 2009, Azziz, Carmina et al. 2016). Women with PCOS are 15 times 
more likely to be infertile than those without, and this is independent of obesity (Azziz, 
Carmina et al. 2016). Studies have also shown that if women with the syndrome are successful 
in conceiving, they are then faced with increased risks of pregnancy associated complications 
(Glueck, Awadalla et al. 2000, Glueck, Wang et al. 2004, Azziz, Carmina et al. 2016) as well 
as increased risk factors to infants born to affected women including higher risk of being large 
for gestational age and having a low Apgar score (that assesses the condition of the newborn by 
measuring factors such as breathing effort, heart rate, muscle tone, reflexes and skin colour) 
(Azziz, Carmina et al. 2016). 
The fibrinolytic system has been shown to have a number of roles other than its involvement in 
the breakdown of thrombi at a system level; this has been shown to have a critical role in 
ovulation processes. In animal models PAI-1 and plasminogen are key components of 
ovulation regulation (Politis, Srikandakumar et al. 1990). Degradation of the follicular layers is 
necessary for oocyte escape. Rupture of the ovarian follicles is associated with a net increase in 
plasmin activity, achieved following an increase in tPA and/or uPA which convert plasminogen 
to active plasmin, and a reduction in PAI-1(Politis, Srikandakumar et al. 1990). Plasminogen 
plays a central role in ovarian follicle extracellular matrix degradation as well as regulation of 
proteins involved in follicular rupture (Cao, Sahmi et al. 2004). The importance of these 
markers in ovulation processes have also been identified in human studies with tPA found in 
female ovarian granulosa cells and within the follicular fluid and PAI-1 also in theca cells 
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(Beers 1975, Piquette, Crabtree et al. 1993, Atiomo, Hilton et al. 2000). Few studies have 
evaluated these fibrinolytic/proteolytic system markers and inhibitors within the PCOS ovaries 
in either humans or in animal models though plasminogen was found to be degraded within the 
follicular fluid of the ovary in women with PCOS (Ambekar, Kelkar et al. 2015) and no 
significant difference in PAI-1 antigen levels in the ovaries of PCOS women versus controls 
have been observed (Atiomo, Hilton et al. 2000). In contrast PAI-1 was found to be prevalent 
in the PCOS ovary but lacking or scant in normal human ovaries (Devin, Johnson et al. 2007). 
Abnormal levels/function of fibrinolytic parameters and inhibitors may, at a systemic level 
contribute to aberrant haemostasis and thrombosis and be linked to CVD and VTE, however at 
a local ovarian level this/these haemostatic distortion/s may contribute to aberrant ovulation 
and have the potential to explain, at least in part, some of the reasons behind the frequent 
fertility problems noted in women with PCOS. 
Women with PCOS also have elevated risks of pregnancy associated complications (Glueck, 
Awadalla et al. 2000, Glueck, Wang et al. 2004, Azziz, Carmina et al. 2016).Women with the 
syndrome have a markedly increased rate of miscarriage with an estimated 44% of pregnancies 
resulting in foetal loss (Glueck, Wang et al. 1999). Early pregnancy loss occurs in around      
30-50% of PCOS women versus only 10-15% of those in the general population 
(Kamalanathan, Sahoo et al. 2013). Pregnancy associated complications including increased 
rates of abortion may potentially be related to an aberrant haemostatic and fibrinolytic system, 
following increased risks of thrombi formation and placental insufficiency. It is well accepted 
that pregnancy, for those in the general population, is a known hypercoagulable state, likely to 
ensure cessation of bleeding following delivery. Increase in clotting factors occurs during 
pregnancy as well as a fall in fibrinolysis (Shan, Wang et al. 2013). PAI-1 activity has been 
demonstrated as an independent risk factor for increased miscarriage rates (Glueck, Wang et al. 
1999). Studies which evaluated the use of metformin and effects on birth outcomes in pregnant 
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women with PCOS noted correlations between PAI-1 and miscarriage rates with improvement 
in live births following a reduction in PAI-1 however the increased miscarriage rates persisted 
in women where PAI-1 activity increased or remained unchanged during treatment (Palomba, 
Orio et al. 2005, Glueck, Sieve et al. 2006, Kamalanathan, Sahoo et al. 2013). Furthermore, a 
recent study that looked into the haemostatic and fibrinolytic potential of pregnant women with 
PCOS during the first trimester of pregnancy noted that pregnant females with the syndrome 
are more prone to a prothrombotic state (Shan, Wang et al. 2013).  
 
1.9 Summary and research gaps 
PCOS is a highly prevalent disorder with reproductive, psychological and metabolic features 
with increased CVD risk factors. Aetiology/ies is/are still unknown and women affected by the 
syndrome can present with a wide-range of clinical features making both diagnosis and 
treatment a significant challenge. Haemostatic abnormalities have an association with and a 
demonstrated pathophysiological role in CVD in non-PCOS populations, yet appear unexplored 
in PCOS. The haemostatic system is highly intricate and a comprehensive and systematic 
assessment is needed to ensure accurate evaluation. Additionally, the OCP, which presents with 
well-accepted risks of venous thromboembolism, is frequently prescribed to this group of 
women. The additional proteolytic role of the fibrinolytic system markers and inhibitors also 
needs to be investigated further within the ovary of women with PCOS to explore aetiology/ies 
of PCOS and assist with future treatment options including for the frequent infertility noted in 
women with the syndrome. 
Key research gaps remain in this area and include the need for: 
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1. An in-depth review of the literature to identify the state of the haemostatic system in 
women with PCOS and evaluate potential relationships to the aberrant metabolic and 
hormonal features frequently present; 
2. A comprehensive and systematic analysis of the overall haemostatic system and its 
components in women with PCOS and review of links to metabolic and hormonal 
parameters to identify potential underlying causes or improved treatments strategies; 
3. An in-depth review of the literature to identify the state of the haemostatic system in 
women with PCOS following commonly and currently prescribed therapies such a 
high- and low-dose OCP and metformin as well as review of potential 
effects/relationships to metabolic and hormonal markers; 
4. Clear demonstrable evidence of the haemostatic effects in women with PCOS following 
administration of commonly prescribed therapies such a high- and low-dose OCP and 
metformin and review of potential effects/relationships to metabolic and hormonal 
markers; 
5. A better understanding of the role fibrinolytic/proteolytic markers and inhibitors have in 
the PCO and in PCOS.  
 
1.10 Aims of the Thesis 
Given the gaps in our knowledge, the body of work presented in this thesis aims to: 
a) Review the literature to evaluate for a relationship between PCOS and disturbed 
haemostasis, including assessment of any associations between haemostatic markers 
and metabolic and hormonal parameters in women with the syndrome.(Chapter 2) 
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b) Comprehensively and systematically assess the haemostatic system in an established 
case-controlled cohort of lean and overweight women with and without PCOS. 
(Chapter 3) 
c) Assess the haemostatic system in a cross-sectional study of overweight women with 
PCOS following commonly prescribed therapies such a higher- and low-dose OCP and 
metformin and identify potential effects/relationships to metabolic and hormonal 
markers. (Chapter 4) 
d) Evaluate and compare the expression and potential roles of fibrinolytic/proteolytic 
markers: plasminogen, plasmin, tPA, uPA and inhibitor PAI-1 in the PCOS ovary and 
in normal ovaries using ovarian tissue from a PCOS mouse model and normal control 
mice, respectively. (Chapter 5) 
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 CHAPTER 2: Haemostatic Abnormalities and Relationships to Metabolic 
and Hormonal Status in Polycystic Ovarian Syndrome 
 
2.1 Introduction 
PCOS is diagnosed based on hyperandrogenism (clinical and/or biochemical), ovulatory 
dysfunction and polycystic ovaries on ultrasound. Aetiological factor(s) include both genetic 
and environmental/lifestyle factors contributing to both insulin resistance and 
hyperandrogenism. It is one of the most common disorders of females of reproductive age, yet 
as a syndrome, it is difficult to diagnose and treat (Teede and Shorakae 2017). Clinical findings 
include reproductive, psychological and significant metabolic features. The metabolic 
abnormalities predispose patients to type II diabetes and CVD. Haemostatic abnormalities are 
closely related to metabolic abnormalities and to CVD in non-PCOS populations.  
A comprehensive review of the literature of the haemostatic system in PCOS must/should 
systematically evaluate all appropriate markers of its major components/systems including 
those of the primary haemostatic system/response, secondary haemostasis or the coagulation 
cascade and inhibitors of coagulation, fibrinolytic system components and relevant inhibitors of 
fibrinolysis as well as assess global markers of haemostasis and fibrinolysis, as a number of the 
haemostatic components have both pro-thrombotic and anti-thrombotic outcomes (see Section 
1.6). This must also review and identify if studies evaluated for markers which interfere with 
haemostatic function including BMI, age, relevant medications and smoking status; if studies 
were adequately powered and if sufficient evidence is available to draw any definitive 
conclusions. 
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In this context and to evaluate the primary haemostatic system, studies assessing both 
quantitative and qualitative markers of platelets in women with PCOS were evaluated. This 
included evaluation of platelet numbers but also platelet structure and function through a 
review of the literature of mean platelet volume (MPV); platelet activation and aberrant 
thrombotic stimuli were also investigated by examining the literature for soluble CD40 ligand 
(sCD40L) and urinary thromboxane metabolite (TXM) in women with the syndrome, as in vivo 
markers of platelet activation (FitzGerald, Pedersen et al. 1983, Oktem, Ozcimen et al. 2009). 
Further assessment of primary haemostasis in women with PCOS was completed through 
investigation of endothelial function by examining its synthesized products including von 
Willebrand factor (vWf) and PAI-1 as well as asymmetric dimethyl-arginine (ADMA), a major 
nitric oxide inhibitor (De Gennaro Colonna, Bianchi et al. 2009). 
Evaluation of secondary haemostasis in the literature was completed through review of all 
individual clotting factors from the coagulation cascade (coagulation factors I through to XIII) 
in women with the syndrome but also by looking into screening tests that measure components 
of this cascade. Prothrombin Time (PT) measures the levels and function of coagulation factors 
I (fibrinogen), II (prothrombin), V, VII and X part of the extrinsic and common pathways in the 
‘classical’ in vitro coagulation cascade (Figure 1.5) through observation of the time taken to 
form a fibrin thrombus following exposure to a tissue factor-rich substance such as 
thromboplastin (in addition to phospholipids and calcium) (Turgeon 2017). Activated Partial 
Thromboplastin Time (APTT) measures the intrinsic and common pathways (Figure 1.5), and 
determines the levels and function of all clotting factors of the cascade with the exception of 
factors VII and XIII (Turgeon 2017). APTT reagents usually contain activating agents 
including phospholipids and negatively charged particles such as kaolin, silica, ellagic acid or 
celite to improve responsiveness and reproducibility of the test (Fritsma, Dembitzer et al. 
2012). Thrombin time (TT) assesses formation of polymerized fibrin by thrombin and will 
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identify the presence of inhibitors of thrombin or substances that affect fibrin formation 
(Turgeon 2017).  
A comprehensive review of the literature for all major inhibitors of haemostasis including AT, 
TFPI, Protein C and its cofactor Protein S as well as APC in women with the syndrome was 
performed. Review of principal fibrinolytic system markers plasminogen (and active plasmin) 
as well as activators of plasminogen including tPA and uPA and inhibitors of fibrinolysis     
PAI-1, α2 antiplasmin, TAFI and α2 macroglobulin was also carried out for women with 
PCOS.  
Global markers of coagulation and fibrinolysis were explored including the Global Fibrinolytic 
Capacity (GFC), a test which evaluates the amount of fibrin degradation products (FDP) 
generated when a freeze-dried fibrin clot is stopped by the addition of aprotinin (an anti-
fibrinolytic molecule) (Yildiz, Haznedaroglu et al. 2002). The level of PF1 & 2, generated 
following conversion of prothrombin to thrombin, were evaluated in the literature in women 
with PCOS to identify both the effectiveness of the coagulation cascade but also the ability of 
some coagulation factors inhibitors to prevent conversion of prothrombin to its active form. 
PF1 & 2 is also a marker of subclinical in vivo coagulation-mediated thrombosis. The 
Thrombin Generation (TG) test, which looks at the haemostatic system overall, evaluating both 
the pro-coagulation effects of the coagulation cascade, but also inhibitory substances that 
prevent the generation of thrombin, mainly TFPI, AT and Protein C was also investigated 
(Chaireti 2013). DDimer (DD) levels were explored in the literature for women with the 
syndrome to identify formation of cross-linked fibrin following coagulation cascade activation 
and simultaneous breakdown by fibrinolysis.  
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Even minor alterations in the levels and/or function of any of the components of the 
haemostatic system can have serious consequences on a patient’s ability to prevent loss of 
blood following vascular harm or to ensure adequate flow of blood following aberrant 
procoagulant stimulus/i within the vasculature. Assessing the haemostatic system in females 
affected by PCOS is critical due to their already increased risk of CVD and VTE to ensure 
appropriate preventative measures are implemented against CVD and venous thrombosis 
development and their complications in the younger population group as well as appropriate 
management strategies are introduced for those already in a high-risk range. 
 
2.2 PCOS and the Primary Haemostatic System  
Assessment of primary haemostasis (in females with PCOS) can be undertaken by evaluating 
its principal components, namely platelets and the vascular endothelium (Figure 2.1). 
2.2.1 Platelet volume, number and function  
Platelets with a high volume have been shown to have a higher thrombotic potential (Gursoy, 
Ertugrul et al. 2006); these aggregate more rapidly, have elevated levels of Thromboxane A2 (a 
platelet aggregation agonist) as well as have increased levels of some procoagulant surface 
proteins (Kebapcilar, Taner et al. 2009). Enhanced platelet aggregability may also increase the 
risk of thrombosis and of CVD. Increased mean platelet volume (MPV) is considered an 
independent risk factor for CVD (Gursoy, Ertugrul et al. 2006). It is also well accepted that 
increased platelet numbers are linked to increased CVD risks. 
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Figure 2.1 Relationships and interactions between endothelial function, platelet activation and 
aggregation, inflammation, coagulation and fibrinolysis in PCOS. Studies have shown 
abnormal platelet function, inhibition of endothelial function and inhibition of fibrinolysis in 
PCOS resulting in a net prothrombotic phenotype. ADP, adenosine diphosphate; ADMA, 
asymmetric dimethylarginine; CD40L, CD40 ligand; FVIIa, activated factor VII; GPIIb/IIIa, 
platelet glycoprotein IIb/IIIa; PAI-1, plasminogen activator inhibitor 1; PAR, protease activated 
receptor; PROTEIN C/S, activated protein C and protein S complex; tPA, tissue plasminogen 
activator; TAFI, thrombin activatable fibrinolysis inhibitor; TTM, thrombin-thrombomodulin 
complex; TxA2, thromboxane A2; vWf, Von Willebrand factor. 
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Earlier studies demonstrated elevated platelet volume in PCOS versus controls (Gursoy, 
Ertugrul et al. 2006, Kebapcilar, Taner et al. 2009). More recent studies however have revealed 
equivocal results with some noting no significant difference in MPV between lean women with 
PCOS and controls (Dogan, Arduc et al. 2014, Silfeler, Kurt et al. 2014); or increased MPV in 
only obese PCOS versus controls (Cakiroglu, Vural et al. 2016) while increased MPV has also 
been observed in lean counterparts (Yilmaz, Duran et al. 2016). Silfeler et al (Silfeler, Kurt et 
al. 2014) suggest that obesity drives the increased MPV in PCOS though Kucur et al (Kucur, 
Gozukara et al. 2015) have noted increased MPV in PCOS versus controls independent of 
BMI. A positive correlation between MPV and IR has been observed (Kebapcilar, Taner et al. 
2009, Kucur, Gozukara et al. 2015) but not always (Gursoy, Ertugrul et al. 2006). Differences 
in relationships between MPV and testosterone levels have been observed (Gursoy, Ertugrul et 
al. 2006, Kebapcilar, Taner et al. 2009),while in one study a negative correlation between 
androgens and MPV was noted (Dogan, Arduc et al. 2014).  
Platelet numbers were shown to be higher in PCOS in one study (Luque-Ramirez, Mendieta-
Azcona et al. 2009) and similar to controls in most (Dereli, Ozgen et al. 2003, Gursoy, Ertugrul 
et al. 2006, Kebapcilar, Taner et al. 2009, Cakiroglu, Vural et al. 2016, Yilmaz, Duran et al. 
2016). However, no correlations between platelet numbers and free testosterone levels have 
been observed (Kebapcilar, Taner et al. 2009). 
Earlier studies have noted platelet dysfunction in women with PCOS compared to controls with 
one study showing increased platelet aggregation following agonist stimulation (ADP, 
collagen, epinephrine) (Dereli, Ozgen et al. 2003) and the other impairment of platelet 
responsiveness to the anti-aggregation effects of NO, independent of obesity (Rajendran, 
Willoughby et al. 2009). A recent small study performed with 21 PCOS and 19 BMI- and    
age-matched controls showed no significant difference in platelet function between the two 
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groups following stimulation with ADP or inhibition by prostacyclin (Kahal, Aburima et al. 
2013).  
Investigation of platelet activation and exocytosis and abnormal thrombotic stimulus (on 
platelets) can be performed using soluble CD40 ligand (sCD40L), which is a 
thromboinflammatory marker. With 95% of its circulating levels originating from activated 
platelets (Oktem, Ozcimen et al. 2009), elevated sCD40L levels represent an indirect marker of 
in vivo platelet activation. Elevated sCD40L levels may represent ongoing subclinical platelet-
mediated thrombosis and are highly correlated with cardiovascular outcome (Lutgens, van 
Suylen et al. 2003). Identification of an abnormal procoagulant stimulus on a normal primary 
haemostatic system can also be undertaken by evaluation of thromboxane metabolite (TXM). 
Thromboxane A2/B2 metabolite, a major prostanoid synthesized by platelets, can be measured 
through a sensitive, specific and non-invasive method known as urinary thromboxane 
metabolite (Eldor, Lellouche et al. 1991). Enhanced urinary TXM represents a time-integrated 
index of ongoing platelet activation in vivo (FitzGerald, Pedersen et al. 1983). This method 
would therefore demonstrate superiority to platelet aggregation studies which assess platelet 
functionally in vitro and only for the small period of time during which the blood sample was 
collected. 
In general sCD40L levels in PCOS have been shown to be elevated compared to controls 
(Zwirska-Korczala, Sodowski et al. 2008, Oktem, Ozcimen et al. 2009, Kebapcilar, Kebapcilar 
et al. 2011, El-Mesallamy, Abd El-Razek et al. 2013) though in a recent study reduced sCD40L 
levels in PCOS were observed in comparison to controls, irrespective of body weight (Sarray 
and Almawi 2016). Oktemet al found that sCD40L levels were affected independently of the 
metabolic (fasting insulin and HOMA-IR) or hormonal (total and free testosterone) profile in 
PCOS (Oktem, Ozcimen et al. 2009). In another study no correlation between sCD40L and 
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hyperandrogenaemia or IR was observed (Kebapcilar, Bilgir et al. 2010). A more recent study 
by El-Mesallamy et al found an association between sCD40L and IR indices (El-Mesallamy, 
Abd El-Razek et al. 2013). There have not been any publications identified to date assessing the 
levels of urinary TXM in women with PCOS. 
Although there is disagreement in the literature, available data indicate a potential role for 
abnormal platelet activation/function, suggesting disturbed primary haemostasis in PCOS, 
although the mechanism/s by which these effects are exerted are unclear. The cause of the 
platelet abnormalities or their aberrant activation is uncertain. Further research is needed to 
determine the relationships of MPV, sCD40L, urinary TXM and possibly platelet numbers to 
metabolic and hormonal profiles in PCOS. Insulin is believed to affect platelet function, and 
variation in insulin sensitivity can affect platelet responses to various agonists (Dereli, Ozgen et 
al. 2003). Platelet dysfunction in PCOS, following impairment of responsiveness to NO, was 
also shown to be independent of IR (Rajendran, Willoughby et al. 2009). Further research is 
necessary to both demonstrate the presence of abnormal platelet function/activation in PCOS 
compared to matched controls and ascertain whether this is linked to IR. Assessment of platelet 
activation following OCP administration in PCOS may also identify thrombotic and CV risk 
factors, which are important considering the frequency of OCP use in PCOS. 
2.2.2 Endothelial function 
A dysfunctional endothelium has been linked with an increased risk of CV events following its 
key contribution to atherosclerosis (Moran, Hutchison et al. 2009). Its function can be assessed 
indirectly through measurement of its synthesized products, namely vWf and PAI-1as well as 
through assessment of ADMA, a major NO inhibitor. These products, along with an abnormal 
endothelium, have all been independently linked to type 2 diabetes, further increasing the 
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potential for CV injury. ADMA is also an independent marker for CV morbidity and mortality 
(Heutling, Schulz et al. 2008). 
Most studies have revealed that vWf levels in PCOS are similar to those of controls (Dahlgren, 
Janson et al. 1994, Kelly, Lyall et al. 2002, Kuscu and Var 2009, Moran, Hutchison et al. 2009, 
Manneras-Holm, Baghaei et al. 2011) though others have shown increased levels of the 
endothelial dysfunction marker in females with the syndrome versus age- and BMI-matched 
controls (Foltyn, Strzelczyk et al. 2011, Koiou, Tziomalos et al. 2012). One study showed a 
positive link between insulin and vWf antigen (Dahlgren, Janson et al. 1994) and others 
between the latter and triglycerides (Dahlgren, Janson et al. 1994, Foltyn, Strzelczyk et al. 
2011), suggesting a potential link between vWf and the metabolic system. A larger sample size 
and age-matched controls in an earlier study by Kelly et al would have assisted in clarifying 
these findings (Kelly, Lyall et al. 2002). 
Support for endothelial dysfunction in PCOS is based on the majority of observations in the 
literature noting elevated ADMA levels in PCOS (Charitidou, Farmakiotis et al. 2008, 
Heutling, Schulz et al. 2008, Ozgurtas, Oktenli et al. 2008, Moran, Hutchison et al. 2009, 
Rajendran, Willoughby et al. 2009, Moran, Cameron et al. 2011, Bayrak, Dursun et al. 2012, 
Choi, Yang et al. 2012). Some however have reported no significant differences in ADMA 
levels between PCOS and controls (Demirel, Bideci et al. 2007, Pamuk, Torun et al. 2010, 
Soyman, Noyan et al. 2011, Karakurt, Carlioglu et al. 2014). A meta-analysis conducted by 
Toulis et al revealed elevated ADMA levels in PCOS versus controls (Toulis, Goulis et al. 
2011). Results of correlation studies are conflicting. ADMA levels have been found to correlate 
with IR markers (Heutling, Schulz et al. 2008, Moran, Hutchison et al. 2009, Yildizhan, Ilhan 
et al. 2011, Elci, Kaya et al. 2017) and androgens (Heutling, Schulz et al. 2008, Bayrak, Dursun 
et al. 2012, Choi, Yang et al. 2012), whereas others have not observed any significant links 
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(Demirel, Bideci et al. 2007, Charitidou, Farmakiotis et al. 2008, Pamuk, Torun et al. 2010, 
Turkcuoglu, Engin-Ustun et al. 2011). It has been suggested that body weight may affect 
ADMA levels (Kielstein, Donnerstag et al. 2006, Meinitzer, Puchinger et al. 2007), but not all 
studies have used BMI-matched controls (Demirel, Bideci et al. 2007, Rajendran, Willoughby 
et al. 2009). 
In general, the level and/or activity of PAI-1 is elevated in PCOS (Sampson, Kong et al. 1996, 
Atiomo, Bates et al. 1998, Macut, Micic et al. 2001, Sills, Drews et al. 2003, Diamanti-
Kandarakis, Palioniko et al. 2004, Glueck, Wang et al. 2004, Orio, Palomba et al. 2004, 
Carmassi, De Negri et al. 2005, Lin and Yongmei 2008, Moran, Hutchison et al. 2009, Oral, 
Mermi et al. 2009, Manneras-Holm, Baghaei et al. 2011, Koiou, Tziomalos et al. 2012, Moran, 
Noakes et al. 2012, Aziz, Sidelmann et al. 2015, Elci, Kaya et al. 2017) although some have 
observed no significant differences compared to controls (Dahlgren, Janson et al. 1994, 
Atiomo, Fox et al. 2000, Atiomo, Hilton et al. 2000, Yarali, Yildirir et al. 2001, Slopien, 
Lewandowski et al. 2006, Koiou, Tziomalos et al. 2012, de Mendonca-Louzeiro, Annichino-
Bizzacchi et al. 2013). A meta-analysis of over 800 women revealed that both PAI-1 antigen 
levels and activity are elevated in females with the syndrome when compared to controls 
(Toulis, Goulis et al. 2011). A correlation between PAI-1 and insulin or insulin sensitivity 
markers in PCOS has been observed in most studies (Dahlgren, Janson et al. 1994, Sampson, 
Kong et al. 1996, Sills, Drews et al. 2003, Carmassi, De Negri et al. 2005, Moran, Hutchison et 
al. 2009, Manneras-Holm, Baghaei et al. 2011, de Mendonca-Louzeiro, Annichino-Bizzacchi et 
al. 2013, Aziz, Sidelmann et al. 2015) with only few noting the contrary (Sills, Drews et al. 
2003, Orio, Palomba et al. 2004, Koiou, Tziomalos et al. 2012). Recently it was suggested that 
PAI-1 may be used as a biomarker to predict IR in women with (and without) PCOS (Cassar, 
Teede et al. 2015). It is unclear if PAI-1 levels/activity correlate with androgens because some 
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studies suggest a link (Carmassi, De Negri et al. 2005, Aziz, Sidelmann et al. 2015) while 
others did not (Sampson, Kong et al. 1996, Orio, Palomba et al. 2004). 
Conclusions from many of the studies that assess PAI-1 (and ADMA) in PCOS are limited by 
suboptimal experimental design and between-study heterogeneity (Toulis, Goulis et al. 2011). 
Both age and weight are known to affect PAI-1(Vague, Juhan-Vague et al. 1986, Heinrich, 
Dirkeskersting et al. 1992, De Pergola, De Mitrio et al. 1997). Some of the earlier studies were 
neither age- nor weight-matched (Glueck, Wang et al. 2004, Carmassi, De Negri et al. 2005) or 
only matched for age (Glueck, Morrison et al. 2008). In some there was a significant difference 
in age (Yarali, Yildirir et al. 2001) or in weight (Atiomo, Bates et al. 1998) between PCOS and 
controls. Some would have been supported by larger sample sizes (Atiomo, Bates et al. 1998, 
Slopien, Lewandowski et al. 2006, Oral, Mermi et al. 2009). Some selected participants other 
than healthy controls (Dahlgren, Janson et al. 1994) and others indicated elevated PAI-1 levels 
in PCOS versus controls, but did not reach statistical significance (p>0.05) (Macut, Micic et al. 
2001). One study did not mention whether the PCOS females were on medications known to 
interfere with PAI-1(Lin and Yongmei 2008). 
Although discrepancies are noted, correlation studies reveal a link between PAI-1 and the 
aberrant metabolic (and potentially hormonal) profile in PCOS. If this is indeed the case, it is 
also important to determine whether IR and consequent hyperinsulinaemia are a result of 
abnormal endothelial function limiting insulin action. Alternatively, the disturbed metabolic 
system in PCOS may have caused endothelium dysfunction. Insulin induces vasodilation 
(Carmassi, De Negri et al. 2005), and high levels may contribute to hyperstimulation of the 
endothelium, potentially resulting in dysfunction. Studies have shown that PAI-1 declines 
following metformin administration or weight loss, suggesting IR as a contributor (Ibanez, 
Aulesa et al. 2002, Sills, Drews et al. 2003). However, intervention studies using OCP reduced 
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ADMA levels in PCOS despite increases in IR (Charitidou, Farmakiotis et al. 2008, Heutling, 
Schulz et al. 2008). Insulin can also directly affect PAI-1 levels by up regulating its 
transcription (Sills, Drews et al. 2003).  
While earlier research is generally of suboptimal quality and studies show significant between-
study heterogeneity with conflicting results including in some studies completed more recently, 
the overwhelming majority of studies reveal an aberrant endothelium in PCOS, as reflected by 
elevated ADAM levels and PAI-1 levels/activity, that is related to the aberrant metabolic and 
potentially hormonal profiles. Further research with robust studies assessing endothelial 
function and its potential links to the metabolic and hormonal profiles in PCOS will help to 
further clarify or confirm these outcomes and may yield valuable aetiological information, 
potentially providing future therapeutic targets.  
 
2.3 PCOS and Secondary Haemostasis  
Assessment of secondary haemostasis in PCOS can be carried out by examining significant 
coagulation factors and pathways within the coagulation cascade (Figure 2.1).  
2.3.1 Coagulation Factor FVII and Fibrinogen 
There is evidence that elevated plasma levels of coagulation factor VII (fVII) are independently 
linked to risks for coronary heart disease (Kelly, Lyall et al. 2002), cardiovascular death 
(Dahlgren, Janson et al. 1994) and atherosclerosis due to its affinity to lipoproteins (Dahlgren, 
Janson et al. 1994). Elevated fibrinogen concentrations have been linked with coronary artery 
disease (Dahlgren, Janson et al. 1994) and MI (Yildiz, Haznedaroglu et al. 2002, Karakurt, 
Gumus et al. 2008) and they are a known risk factor for atherosclerosis (Nasiek, Kos-Kudla et 
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al. 2007). Fibrinogen may promote thrombosis because it affects platelet aggregability and 
increases plasma viscosity (Nasiek, Kos-Kudla et al. 2007).  
Studies on fVII in PCOS have yielded conflicting results. One study reported a significantly 
higher mean concentration of fVII antigen (Dahlgren, Janson et al. 1994),whereas others 
observed no significant differences compared to controls (Kelly, Lyall et al. 2002, Yildiz, 
Haznedaroglu et al. 2002). Positive correlations to insulin in PCOS and triglycerides in both 
PCOS and controls with fVII antigen were noted (Dahlgren, Janson et al. 1994). A recent study 
evaluating tissue factor, the receptor for coagulation fVII, revealed elevated levels in lean 
women with PCOS compared to lean controls, that positively correlated to androgens and 
inversely to insulin sensitivity (Gonzalez, Kirwan et al. 2013).  
Fibrinogen levels in PCOS were observed to be similar (Kelly, Lyall et al. 2002, Yildiz, 
Haznedaroglu et al. 2002, Andiran, Yordam et al. 2005, Slopien, Lewandowski et al. 2006, 
Nasiek, Kos-Kudla et al. 2007, Karakurt, Gumus et al. 2008, Kebapcilar, Taner et al. 2009, 
Pamuk, Torun et al. 2010, Glintborg, Sidelmann et al. 2015), lower than (Dahlgren, Janson et 
al. 1994) or higher than (Atiomo, Bates et al. 1998, Erdogan, Karadeniz et al. 2008, Heutling, 
Schulz et al. 2008, Bagir, Bakiner et al. 2016) those of controls. No correlation between 
fibrinogen and free testosterone levels in PCOS was observed (Kebapcilar, Taner et al. 2009), 
whereas a direct association between fibrinogen and insulin levels was noted (Dahlgren, Janson 
et al. 1994). 
Earlier studies evaluating fibrinogen in PCOS would also have benefited from larger samples 
sizes and/or weight- or age-matched controls (Atiomo, Bates et al. 1998, Kelly, Lyall et al. 
2002, Andiran, Yordam et al. 2005, Slopien, Lewandowski et al. 2006, Karakurt, Gumus et al. 
2008). Smoking and OCP are known to increase fibrinogen levels (Dahlgren, Janson et al. 
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1994). Some studies investigated only OCP effects (Yildiz, Haznedaroglu et al. 2002, Slopien, 
Lewandowski et al. 2006, Karakurt, Gumus et al. 2008) or did not clarify confounders such as 
smoking status (Erdogan, Karadeniz et al. 2008). 
2.3.2 Coagulation Screening Tests 
Assessing PT, APTT and TT in PCOS can assist in evaluating the functionality of clotting 
pathways in the coagulation cascade where abnormal results may be associated with a 
procoagulant state. PT assesses the extrinsic (and common) coagulation pathway, APTT 
measures factors of the intrinsic (and common) pathway of the coagulation cascade and TT 
evaluates for fibrin formation and inhibitors of thrombin. 
Studies undertaken to date that looked at PT and APTT in females with PCOS found no 
significant difference in the times measured when compared to controls (Yildiz, Haznedaroglu 
et al. 2002, Andiran, Yordam et al. 2005, Karakurt, Gumus et al. 2008, Kebapcilar, Taner et al. 
2009, Guldas, Altinkaya et al. 2015). Two of these studies (Yildiz, Haznedaroglu et al. 2002, 
Andiran, Yordam et al. 2005) also evaluated the TT in this population group and observed no 
statistically significant differences when compared to controls. Outcomes obtained may have 
been influenced by limitations of some of the studies including a low sample size (Karakurt, 
Gumus et al. 2008) and significant differences in age and weight between PCOS and controls 
(Andiran, Yordam et al. 2005). Kebapcilar et al looked at correlation figures between 
coagulation parameters and hormonal markers and did not find an association between PT and 
APTT with testosterone (Kebapcilar, Taner et al. 2009). No correlation studies with metabolic 
parameters in PCOS were completed for PT, APTT or TT. 
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2.3.3 Other Coagulation Factors  
Only a few studies have evaluated other individual clotting factors within the coagulation 
cascade. Many of these also revealed contradictory findings with one noting elevated factor 
VIII levels in PCOS when compared to controls (Glueck, Wang et al. 2004) and the other 
observed comparable levels between the two groups (Manneras-Holm, Baghaei et al. 2011). 
Yildiz et al  also assessed factors II (thrombin), V and X and found no significant difference 
between women with the syndrome and controls (Yildiz, Haznedaroglu et al. 2002). 
Further studies assessing coagulation factor fVII and fibrinogen, and potentially other 
coagulation cascade factors and pathways and continuing to use adequately powered and robust 
study protocols and correlating to metabolic and/or hormonal parameters, are necessary to 
address the inconsistency of results of studies published to date. Inclusion of markers of 
subclinical in vivo coagulation-mediated thrombosis, such as PF1 & 2 (Ota, Wada et al. 2008), 
would clarify the role of coagulation in PCOS-associated cardiovascular risk. Apart from my 
paper (Burchall, Piva et al. 2016), I am unaware of any published studies investigating PF1 & 2 
in PCOS. 
 
2.4 PCOS, Inhibitors of Coagulation, Fibrinolytic System and Global Haemostatic & 
Fibrinolytic Markers 
The fibrinolytic system and inhibitors of coagulation act to control excessive or inappropriate 
thrombotic effects. These systems may be important in PCOS for several reasons. Suppression 
of the fibrinolytic system has been associated with endothelial dysfunction and with the 
development of CVD (Yildiz, Haznedaroglu et al. 2002). If a procoagulant state is 
The Haemostatic System in PCOS  
 
59 | P a g e  
 
demonstrated in PCOS within the primary and/or secondary haemostatic systems, it is 
important to identify whether this/these is/are adequately counteracted by fibrinolytic activation 
and inhibitors of coagulation. This can be accomplished by examining the literature for 
individual factors within these systems in women affected by the syndrome but importantly 
following a review of global markers of haemostasis and fibrinolysis (Figure 2.1). 
2.4.1 Coagulation Inhibitors  
Individuals heterozygous for protein C, protein S and AT deficiencies are known to have 
increased risks of thrombosis (Tsanadis, Vartholomatos et al. 2002). AT levels/activity in 
PCOS are either similar to (Yildiz, Haznedaroglu et al. 2002, Andiran, Yordam et al. 2005) or 
higher than (Oral, Mermi et al. 2009) those of women who are not affected by this syndrome. 
Protein C, protein S, and activated protein C percentages have been shown to be comparable to 
those of controls (Oral, Mermi et al. 2009). Relationships between these haemostatic 
parameters and metabolic or hormonal markers have not been explored.  
Gaps in the literature include the need for larger sample sizes assessing these haemostatic 
markers in PCOS and correlations between these and hormonal or metabolic PCOS features. 
Thrombomodulin, which stimulates Protein C activation, has been found to be elevated in 
women with PCOS versus matched controls (Oral, Mermi et al. 2009).  
2.4.2 Thrombin Generation (TG) 
Increased thrombin generation is linked to increased risks for both arterial and venous 
thrombosis (Aziz, Sidelmann et al. 2015). Few studies have been completed to date, apart from 
my paper (Burchall, Piva et al. 2016), that have evaluated TG or thrombin potential in females 
with PCOS. de Mendonca-Louzeiro et al have shown a shorter thrombin generation lag-time 
(time of the lag-phase that follows after addition of activating agent and generation of 
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thrombin) in females with PCOS compared to age- and BMI-matched controls, that can lead to 
a hypercoagulable state (de Mendonca-Louzeiro, Annichino-Bizzacchi et al. 2013). Others 
have noted longer TG lag-time however increased endogenous thrombin potential (noting the 
total amount of thrombin formed) and peak generation of thrombin in PCOS compared to 
controls, independent of other risk factors of CVD (Glintborg, Sidelmann et al. 2015). TG 
measures were related to CRP, fibrinogen, trunk-fat and SHBG (Glintborg, Sidelmann et al. 
2015). 
Further research is needed to evaluate the recently developed TG test that is currently only used 
in research settings (Pabinger and Ay 2009, de Mendonca-Louzeiro, Annichino-Bizzacchi et al. 
2013). However results so far indicate potential increased generation of thrombin that can have 
detrimental effects on the haemostatic system including increased fibrin formation as well as 
increased platelet activation, as thrombin is a well-known and powerful platelet agonist 
(McNicol and Robson 1997). Thrombin has also been involved in the development of 
atherosclerosis, endothelial dysfunction and increased TG measures are noted in patients with 
increased risks for VTE (Borissoff, Spronk et al. 2009, Pabinger and Ay 2009, Glintborg, 
Sidelmann et al. 2015). 
 
2.4.3 Tissue Plasminogen Activator 
Elevated tPA levels in PCOS have been shown to correlate with coronary artery disease and 
independently with chronic heart disease (Kelly, Lyall et al. 2002). In general, tPA levels are 
elevated in PCOS (Kelly, Lyall et al. 2002, Sills, Drews et al. 2003, Lin and Yongmei 2008) or 
only in obese PCOS (Lindholm, Bixo et al. 2010) although others have shown no significant 
differences compared to controls (Carmassi, De Negri et al. 2005, Manneras-Holm, Baghaei et 
al. 2011), despite significant differences in IR between groups in one study (Carmassi, De 
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Negri et al. 2005). tPA levels have also been shown to be higher in PCOS compared to controls 
even after adjustment for insulin sensitivity (Kelly, Lyall et al. 2002). These levels have also 
been correlated with fasting insulin (Lin and Yongmei 2008) and an inverse correlation 
between the insulin sensitivity index and tPA has been suggested (Kelly, Lyall et al. 2002). No 
correlation between tPA and total testosterone has been observed (Kelly, Lyall et al. 2002, Lin 
and Yongmei 2008). Greater inclusion of both age- and BMI-matched controls in some studies 
(Kelly, Lyall et al. 2002, Carmassi, De Negri et al. 2005) as well as information on relevant 
medication usage (Lin and Yongmei 2008) would assist interpretation.  
While tPA levels appear elevated in PCOS, research has shown that these predominantly reflect 
tPA-PAI-1 complexes, formed due to elevated PAI-1 levels (Carmassi, De Negri et al. 2005, 
Lin and Yongmei 2008). It is unclear whether elevated tPA levels are linked with elevated 
insulin levels. Although a link may be plausible, especially following observations of a 
reduction in tPA antigen levels in PCOS following metformin treatment (Kelly, Lyall et al. 
2002), the data are conflicting. Further research is thus necessary, including studies comparing 
tPA levels in BMI- (and age-) matched insulin-sensitive and IR PCOS women both pre- and 
post-pharmacological insulin and androgen modulation. 
2.4.4 Plasminogen 
Although a significant member of the fibrinolytic system, only two studies have been published 
assessing plasminogen in PCOS (apart from my paper Burchall et al. 2016), one showing 
similar (Yildiz, Haznedaroglu et al. 2002) while the other lower activity compared to controls 
(Slopien, Lewandowski et al. 2006) with no correlation to metabolic markers completed. 
Additional research is needed to assess plasminogen in PCOS and should incorporate 
correlation analyses to identify any links with the hormonal and metabolic systems. 
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2.4.5 Global Fibrinolytic Capacity 
GFC is a superior assay for identifying net fibrinolytic potential rather than examining 
individual fibrinolytic components (Yildiz, Haznedaroglu et al. 2002). A reduced GFC is 
associated with a number of CV risk factors in healthy individuals (Yildiz, Haznedaroglu et al. 
2002). 
GFC has been shown to be significantly lower in PCOS versus controls (Yildiz, Haznedaroglu 
et al. 2002). It has also been shown to be significantly lower in young girls with PCOS 
compared to young girls controls (Andiran, Yordam et al. 2005). Limitations of this study 
however included a small sample size and a lack of age- and BMI-matched controls. A positive 
correlation between GFC level and median fasting glucose:insulin ratio has been observed, 
with a negative correlation between GFC and both free testosterone and fasting insulin levels 
(Andiran, Yordam et al. 2005). In contrast, no correlation between GFC and IR parameters 
(fasting, insulin, HOMA-IR, and fasting glucose:insulin levels) has also been observed, and a 
negative correlation with testosterone and free testosterone levels (Yildiz, Haznedaroglu et al. 
2002). 
Although it is an effective and sensitive method for assessing fibrinolytic activity in large study 
populations (Yildiz, Haznedaroglu et al. 2002), further research is needed on the accuracy and 
clinical relevance of the GFC. More research is also needed to assess GFC in PCOS and 
relationships to hormonal and metabolic markers, given the small sample sizes and inconsistent 
findings to date. 
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2.4.6 D-Dimers (DD) 
DD levels, as a marker of fibrin formation and degradation, have been shown to be elevated in 
PCOS by some (Kebapcilar, Taner et al. 2009, Oral, Mermi et al. 2009) though unchanged in 
other studies (Yildiz, Haznedaroglu et al. 2002, Andiran, Yordam et al. 2005, Karakurt, Gumus 
et al. 2008, Manneras-Holm, Baghaei et al. 2011, de Mendonca-Louzeiro, Annichino-Bizzacchi 
et al. 2013) when compared to controls. A correlation between DD levels and free testosterone 
levels in PCOS have been observed, whereas relationships with IR have not been explained 
(Kebapcilar, Taner et al. 2009). Further studies to confirm the levels of DD in women with 
PCOS in comparison to controls and the clinical significance of these are warranted 
(Wannamethee, Lowe et al. 2005, Oral, Mermi et al. 2009). Where elevated DD levels occur in 
PCOS, these are likely to represent increased subclinical fibrin generation, rather than elevated 
fibrin degradation, because the global fibrinolytic capacity is reduced. 
All in all inhibitors of coagulation, fibrinolytic system markers and global indicators of 
haemostasis and fibrinolysis appear poorly explored with significant further robust research 
studies required to accurately evaluate these markers and correlate to the aberrant metabolic 
and hormonal profiles in women with PCOS. 
 
2.5 PCOS and Inhibitors of Fibrinolysis 
Important inhibitors of fibrinolysis include PAI-1, α2 antiplasmin, α2 macroglobulin and TAFI. 
PAI-1 (discussed previously in section 2.2.2) and TAFI may be relevant in PCOS given their 
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links to CVD risk and to venous thrombosis (van Tilburg, Rosendaal et al. 2000, Chen, Lee et 
al. 2005) (Figure 2.1). 
2.5.1 α2 antiplasmin and α2 macroglobulin 
α2 antiplasmin is of significance in the population of interest indirectly because of its inhibitory 
effects on plasmin. There have been three studies published evaluating α2 antiplasmin activity 
in PCOS. No significant difference in comparison to controls were observed in females with 
PCOS (Atiomo, Fox et al. 2000, Yildiz, Haznedaroglu et al. 2002) or in obese females with the 
syndrome (Slopien, Lewandowski et al. 2006) versus those of controls. No correlation analyses 
have been completed for the marker with components of the metabolic or hormonal systems. 
Comments in relation to the study design of these research studies have been described earlier. 
Studies that looked at α2 macroglobulin levels in PCOS revealed contradictory findings with a 
small study of 12 PCOS and 12 controls noting reduced levels in the former versus the latter 
(Insenser, Martinez-Garcia et al. 2010) however a more recent study noted no significant 
reductions in the marker in women affected by the syndrome when compared to controls 
(Haoula, Shaw et al. 2014).  
In conclusion, α2 antiplasmin and α2 macroglobulin levels do not appear to be significantly 
different between PCOS and controls.  
2.5.2 TAFI 
TAFI levels/activity in PCOS have been shown to be elevated (Karakurt, Gumus et al. 2008, 
Oral, Mermi et al. 2009, Guldas, Altinkaya et al. 2015) or similar to controls (Erdogan, 
Karadeniz et al. 2008, de Mendonca-Louzeiro, Annichino-Bizzacchi et al. 2013), whereas 
thrombomodulin, a cofactor responsible for activating TAFI, is also elevated in PCOS (Oral, 
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Mermi et al. 2009). Correlations between TAFI with insulin and HOMA-IR were observed in 
some studies (Oral, Mermi et al. 2009, Guldas, Altinkaya et al. 2015) but not in another 
(Erdogan, Karadeniz et al. 2008). A multiple regression analysis failed to find any significant 
effect of HOMA-IR on TAFI levels (Guldas, Altinkaya et al. 2015). On the other hand, a 
positive correlation between TAFI and total cholesterol and LH but a negative link with     
high-density lipoprotein cholesterol have been noted (Oral, Mermi et al. 2009). Inclusion of 
larger samples sizes would have been appropriate as well as inclusion of BMI-matched PCOS 
and controls in one study (Karakurt, Gumus et al. 2008). 
If a hypofibrinolytic state is confirmed in PCOS, reflected by increased TAFI (and PAI-1) 
levels, the aetiology will need to be explored further. TAFI is synthesized in the liver (Karakurt, 
Gumus et al. 2008), although some reports speculate a megakaryocyte/platelet origin with 
subsequent release into plasma following platelet activation (Schadinger and Boffa 2009). The 
studies described previously indicating a potential for aberrant platelet activation/function 
(Zwirska-Korczala, Sodowski et al. 2008, Oktem, Ozcimen et al. 2009) in PCOS suggest a 
possible link to increased TAFI levels. Likewise, studies to confirm elevated TAFI levels in 
PCOS are required with larger sample sizes and explanations of relationships with the 
abnormal metabolic and hormonal systems. 
 
2.6 Conclusions  
PCOS is a highly prevalent condition in the reproductive-aged female population and is a 
complex disorder with significant clinical heterogeneity, making both diagnosis and treatment 
challenging. PCOS includes metabolic features, endothelial dysfunction, early atherosclerosis, 
and an increased risk of CVD development. Haemostatic abnormalities play an important role 
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in CVD. Exploration of the haemostatic system is therefore important in PCOS to identify its 
contribution to CVD. 
A review of the literature has suggested abnormalities of the haemostatic system in PCOS, 
including abnormal platelet function/activation following observations of high sCD40L and 
potentially MPV. Also, endothelial dysfunction reflected mainly by elevation in ADMA and 
PAI-1, potential increased generation of thrombin, increased tPA levels most likely reflecting 
tPA–PAI-1 complexes, and enhanced inhibition of fibrinolysis reflected by high PAI-1 antigen 
and/or activity and potentially elevated TAFI levels. 
Earlier studies included small sample sizes and lacked BMI- and age-matched controls, which 
are known to affect the haemostatic system, however more recent studies appear to be more 
robust. The existing literature however is still limited, with few studies published and 
contradictory findings relating to markers of haemostasis in women with PCOS remain. 
Correlations between haemostatic parameters and markers of the metabolic and hormonal 
systems also reveal inconsistent findings for most of the research completed.  
Hence, the hypothesis of haemostatic abnormalities contributing to disturbed haemostasis 
including a hypofibrinolytic capacity and/or net prothrombotic state in PCOS remains 
unresolved. Further research on the haemostatic system in PCOS is critical and must 
comprehensively and in a systematic manner using well-designed studies assess the system in 
this important syndrome. Whether haemostatic abnormalities are linked to the abnormal 
hormonal and/or metabolic system/s in PCOS also remains to be elucidated, as these 
relationships have only been explored well at present with markers of endothelial function. 
Such research may inform on the underlying aetiology of PCOS and may lead to novel 
preventative or therapeutic measures targeting metabolic features of PCOS underlying CVD. 
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Evaluation of the effects on the haemostatic system following administration of current 
management strategies to modulate androgens and IR including metformin, OCP, and dietary 
and lifestyle modifications in PCOS may facilitate further insights into probable disturbed 
haemostasis and into relationships with hormonal and metabolic markers in PCOS and, in turn, 
with potential further CVD risk markers. 
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2.7 My Role 
Chapters 1 and 2 contain material published as a paper in Trends in Cardiovascular Medicine, 
however for the purposes of this thesis, to improve structure and understanding, the material in 
this paper was divided into two chapters with addition of relevant information researched and 
acquired during my candidature. A full version of the manuscript can be found on the following 
pages of this thesis. As the first author of this manuscript, I contributed to the conception and 
design of the review that aimed to comprehensively evaluate the literature for haemostatic 
markers in women with PCOS. I regularly liaised with my PhD supervisors and other            
co-authors to develop sound literature evaluation. I independently researched, reviewed and 
analysed the articles to determine eligibility and risk for bias.  
Following consultation I independently performed literature (and data therein) evaluation and 
contributed to data analysis and interpretation. I was responsible for submission for publication. 
This manuscript addressed key gaps relating to the haemostatic system in PCOS and 
relationships to hormonal and metabolic status. It informed my PhD work to address these 
gaps. 
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Original paper published in Trends in Cardiovascular Medicine. Burchall G, Linden MD, 
Teede H, PivaTJ. Hemostatic abnormalities and relationships to metabolic and hormonal status 
in polycystic ovarian syndrome. Trends in Cardiovascular Medicine 2011; 21(1): 6-14. 
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 CHAPTER 3: Comprehensive Assessment of the Haemostatic System in 
PCOS 
 
3.1 Introduction 
PCOS presents with many features that increase the risks of CVD development. Metabolic 
abnormalities include IR, hyperinsulinaemia, dyslipidaemia and increase risks for diabetes 
(Teede, Misso et al. 2011). Between 75-95% of women with PCOS present with IR that is 
thought to contribute to the pathophysiology of this syndrome (Stepto, Cassar et al. 2013). 
Women affected by PCOS are more likely to be overweight/obese than those without the 
syndrome and the incidence and severity of the condition increases with increased weight 
(Teede, Misso et al. 2011). Obesity also exacerbates both IR and hyperandrogenism.          
Two-thirds of non-obese PCOS females are reported to have excessive body fat and central 
visceral adiposity inducing greater IR (Cascella, Palomba et al. 2008).   
The current management strategies used to ameliorate the symptoms of PCOS are highly 
variable in line with the clinical heterogeneity of the syndrome and may also increase the risks 
of CVD (Teede, Misso et al. 2011). The frequently prescribed OCP for PCOS management 
present with well accepted risks of VTE as well as increased risk of arterial thrombotic events 
and arterial dysfunction (Meyer et al. 2007). These risks are further amplified as many of the 
women affected by PCOS are also overweight (Teede, Misso et al. 2011). 
In the previous chapter (Chapter 2), it was noted through a review of the literature that there 
may be an additional cardiovascular risk factor in PCOS, potentially relating to disturbed 
haemostasis, through endothelial dysfunction reflected mainly by elevation in ADMA and   
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PAI-1. Also, potential abnormal platelet function/activation following observations of elevated 
sCD40L and MPV and coagulation through increased generation of thrombin; additionally 
enhanced inhibition of fibrinolysis, as reflected by high PAI-1 antigen and/or activity and TAFI 
levels as well as increased tPA levels most likely reflecting tPA – PAI-1 complexes, was also 
observed. It was also noted that earlier studies evaluating haemostatic factors were performed 
using small numbers of subjects and many of these studies lacked BMI- and age-matched 
controls, factors that are well known to affect the haemostatic system, potentially resulting in 
the contradictory findings observed amongst much of the research on the haemostatic system in 
women with PCOS. More recent studies however showed improved study designs, however 
contradictory outcomes persist. Correlations between the haemostatic parameters and markers 
of the metabolic and hormonal systems also revealed inconsistent findings (or were not 
completed). 
As a consequence of the above considerations, this study aimed to comprehensively assess the 
haemostatic system in women affected by PCOS versus controls and adjusting for age, BMI 
and waist circumference, controlling also for factors such as smoking status and medications 
(such as the OCP) affecting haemostasis. This was achieved through evaluation of haemostatic 
system components including the endothelium (part of the primary haemostatic system), the 
coagulation cascade (secondary haemostatic system), the fibrinolytic system and relevant 
inhibitors as well as assessing the haemostatic system overall. The relationships and effects of 
haemostatic function with/from hormonal and metabolic variables associated with PCOS 
including insulin levels, IR and lipid markers such as cholesterol, LDL, HDL and triglycerides 
were evaluated in addition to correlations made with hyperandrogenism (testosterone) to 
identify potential underlying causes and therapeutic targets. The results from this study were 
published in Seminars in Thrombosis and Hemostasis.  
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3.2 My Role 
Chapter 3 consists of a large case-controlled study investigating the haemostatic system in 
women with and without PCOS. I formed collaborations early in my candidature with Prof 
Helena Teede (Monash Centre for Health Research and Implementation, School of Public 
Health and Preventative Medicine, Monash University) who kindly provided me with the 
biobanked plasma samples needed for this study. I applied for and received an exemption from 
ethics review with the Science, Engineering & Health College Advisory Network of the Human 
Research Ethics Committee of RMIT University (refer to Appendix 1) as this study had 
received ethics approval from the Monash University Standing Committee on Ethics in 
Research Involving Humans (and I had been included as an investigator on the research teams 
for this project). I then selected the relevant citrate specimens (that had been stored at the 
School of Public Health and Preventative Medicine, Monash University, Clayton) and 
transported these to RMIT University (School of Medical Sciences, Bundoora) for testing. I 
was responsible for determining the most relevant markers to measure based on my literature 
review and to explore the optimal methods for assessment. I chose relevant assay kits and 
consumables, advising my supervisor of the ordering requirements (refer to the Materials and 
Methods section of the published paper on the following pages for the sources of the assay kits 
and consumables and methods used to analyse the haemostatic parameters of this study). I 
completed method validation and optimisations for all markers analysed, completed the 
analysis of several of the haemostatic markers including plasminogen, TAFI (results not 
included in final published paper; Refer to Appendix 2) as well as TG, statistically analysed 
and interpreted the data (following consultation with a biostatistician) and wrote the 
manuscript. As a result of my contribution I am first author on this manuscript, which was 
published in Seminars in Thrombosis and Hemostasis.  
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 CHAPTER 4: Common Pharmaceutical Interventions (OCP and 
Metformin) in PCOS and Haemostatic Outcomes 
 
4.1 Introduction 
PCOS presents with increased risks for CVD including metabolic abnormalities such as IR, 
hyperinsulinaemia and dyslipidaemia, as well as obesity (Teede, Misso et al. 2011, Teede, 
Joham et al. 2013). Although it remains a contentious issue, recently published large scale 
studies have reported that women with PCOS have significantly higher rates of CVD as well as 
an increase in VTE (1.5 to 2 fold increased risk) in comparison to those without PCOS (Bird, 
Hartzema et al. 2013, Hart and Doherty 2015). This may be exacerbated by aberrant metabolic 
features as well as a high BMI. However it may also be related to disturbed haemostasis. In 
previous chapters (Chapters 2 and 3) it was suggested that additional CVD and VTE risk 
factors are involved in PCOS, potentially related to aberrant haemostasis including a 
hypofibrinolytic state. 
The increased risks for CVD and VTE may be further exacerbated by current PCOS 
management strategies. First line therapy for PCOS includes lifestyle intervention if overweight 
to combat menstrual disturbances, infertility and CVD risks. Additional pharmaceutical therapy 
includes the OCP, anti-androgens, or metformin to target metabolic and reproductive features. 
Whilst the OCP is indicated for contraception and PCOS treatment, concerns have been raised 
about increased risks of VTE, which are well accepted in the general population. Women 
taking the OCP are 3-5 times more likely to have a VTE event than those that do not (Soares, 
Vieira et al. 2009, van Hylckama Vlieg, Helmerhorst et al. 2009, Stewart and Black 2015). The 
risks however vary depending on oestrogen dose and progesterone type, with lower oestrogen 
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dosages and second generation progesterone preparations having lower risks (Soares, Vieira et 
al. 2009, van Hylckama Vlieg, Helmerhorst et al. 2009, Stewart and Black 2015). A twofold 
increased risk of VTE among women with PCOS taking combined OCP compared to those 
unaffected by the syndrome taking the same drug therapy has been observed (Bird, Hartzema et 
al. 2013). Oestrogen and the OCP have been shown to increase the risks of VTE in the general 
population by affecting many/most coagulation factors and increasing prothrombin (factor II) 
levels, fibrinogen (factor I) and factors VII, VIII and X and by decreasing AT and protein S 
levels; increasing TAFI activity and activated protein C (APC) resistance (Rosing, Curvers et 
al. 2001, van Hylckama Vlieg, Helmerhorst et al. 2009, Szabo and Schaff 2013). While OCP 
may affect some haemostatic factors that exert anticoagulant effects including increasing levels 
of plasminogen and protein C, an overall net pro-coagulant effect is still believed to be present 
(Rosing, Curvers et al. 2001). A net thrombotic effect is noted with use of the combined OCP 
from the oestrogen component but the type of progesterone used may also affect haemostatic 
outcomes. Some third generation progesterone combinations (containing desogestrel or 
gestodene) seem to have greater effects on prothrombin and factor VII as well as greater 
resistance to APC than second generation preparations (levonorgestrel)  (Rosing, Curvers et al. 
2001, van Hylckama Vlieg, Helmerhorst et al. 2009). A recent review on the 
pharmacodynamics of combined oral contraceptives (COC) and effects on the haemostatic 
system has confirmed that a dose related effect of the oestrogen component of COC was noted 
on the haemostatic system with an overall pro-coagulatory effect and parameters, that is only 
party counteracted by fibrinolytic system action, with a net increase in fibrin generation 
(following observations of increased PF1 & 2 and DD levels) (Farris, Bastianelli et al. 2017). 
The progestin component of COC can modulate the actions of oestrogen and the haemostatic 
effects noted however the exact mechanisms by which they do this and ultimate haemostatic 
outcomes are still unclear (Farris, Bastianelli et al. 2017). Research in this area is contentious 
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and ongoing and large studies are needed to determine any definitive outcomes. Increased risks 
of arterial disease including myocardial infarct and ischaemic stroke have also been noted in 
women taking the OCP (Stewart and Black 2015). In women with PCOS, OCP may increase 
VTE risks (Bird, Hartzema et al. 2013) as well as leading to arterial dysfunction, altered 
glucose metabolism and IR (Meyer, McGrath et al. 2007), yet studies on the impact of the OCP 
on the haemostatic system in PCOS are limited with key evidence gaps remaining (Burchall, 
Piva et al. 2017). 
Metformin is also used to treat PCOS (Teede, Misso et al. 2011), where it improves IR, 
menstrual cycles and prevents weight gain (Naderpoor, Shorakae et al. 2015). It increases 
pregnancy rates and may impact on live birth rates, however further study is needed to define 
its exact role and mechanism of action/s in infertility management in PCOS (Teede, Misso et 
al. 2011, Naderpoor, Shorakae et al. 2015). Metformin has been shown to have positive effects 
on the haemostatic system in diabetic patients, a population with known increased VTE risk.  
Metformin reduces the level of coagulation factors VII and XIII, PAI-1 and von Willebrand 
factor (Belfiore and Mogensen 2000, Rojas and Gomes 2013). In a high-risk population, 
metformin may offer additional benefits through positive effects on the haemostatic system, 
however few published studies have examined the impact of metformin on this system. 
To date, studies evaluating the effects of OCP and metformin in PCOS have predominantly 
looked at the efficacy on reproductive and hormonal features, but not on the haemostatic 
system. In this context, this study investigated and compared the haemostatic impact of 
common pharmacological therapies for PCOS, specifically higher-dose OCP (35μg ethinyl 
estradiol [EE]/2mg cyproterone acetate), low-dose OCP with a second generation progestin (20 
μg EE/100 μg levonorgestrel) and an anti-androgen (spironolactone 50 mg b.d.) and metformin 
therapy (1 g b.d.). Similar to the earlier study above (Chapter 3), the present study aimed for a 
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systematic and comprehensive evaluation of the haemostatic system in women with PCOS on 
the aforementioned treatments. Similar haemostatic markers were assessed here as in the 
previous study (see Chapter 3). It was aimed to evaluate the components of the haemostatic 
system including endothelial function (part of primary haemostasis/haemostatic response), the 
coagulation cascade (secondary haemostasis), the fibrinolytic system and relevant inhibitors as 
well as assess global markers of haemostatic function. Finally, relationships between 
haemostatic markers and clinically relevant hormonal and metabolic variables associated with 
PCOS including markers of insulin resistance and hyperandrogenism were also investigated to 
help identify potential aetiological factors of the syndrome as well as assist with improvement 
in current treatment choices. 
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4.2 My Role  
Chapter 4 consists of a large cross-sectional study investigating the haemostatic system in 
women with PCOS on three interventions, namely low- and higher-dose OCP and metformin. I 
initially reviewed the literature which revealed the limited knowledge available on the 
haemostatic effects of the frequently prescribed pharmacological interventions in PCOS. I 
received an exemption from ethics review from the Science, Engineering & Health College 
Advisory Network of the Human Research Ethics Committee of RMIT University (refer to 
Appendix 1) as this study had received ethics approval from the Monash University Standing 
Committee on Ethics in Research Involving Humans. I selected the appropriate citrate 
specimens (that had been stored at the School of Public Health and Preventative Medicine, 
Monash University, Clayton) and transported these from Monash University to RMIT 
University (School of Health & Biomedical Sciences, Bundoora). I was responsible for 
determining key endpoints and assays and sourcing these as well as choosing any relevant 
consumables including advising my supervisor of the ordering requirements (refer to the 
Materials and Methods section of the published paper on the following pages for the sources of 
the assay kits and consumables and methods used to analyses the haemostatic parameters of 
this study). I performed any relevant method validations and optimisations and analysed several 
of the haemostatic markers including plasminogen, TAFI and TG, statistically analysed and 
interpreted the data (following consultation with the biostatistician) and wrote the manuscript. 
As a result of my contribution I am first author on this manuscript, which was published in 
Thrombosis and Haemostasis in 2017.  
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 CHAPTER 5: The Fibrinolytic/Proteolytic System in the PCOS Mouse 
Ovary 
 
5.1 Introduction 
Women with PCOS have increased risks for CVD and VTE likely relating to the aberrant 
metabolic features and high BMI as well as an abnormal haemostatic system. A 
hypofibrinolytic state is present in women with PCOS, relating to increased PAI-1 which 
prevents conversion of pro-enzyme plasminogen to active plasmin. The fibrinolytic system 
components and relevant inhibitors however play a number of roles, apart from their function 
in blood haemostasis and thrombosis. Of importance to research into PCOS is their role in the 
ovulation processes.  
Plasmin has been detected in both the follicular fluid (FF) and granulosa cells (GC) of the 
ovary at the time of or just before rupture of the ovarian follicle in porcine models (Politis, 
Srikandakumar et al. 1990). This suggests that plasminogen is converted to active plasmin at 
the time of ovulation (follicular rupture). To achieve this increased plasmin activity, a decrease 
in inhibitor PAI-1 and an increase in plasminogen activators (tissue plasminogen activator, tPA 
and/or urokinase plasminogen activator, uPA) is needed. Changes in the levels of these markers 
were also observed just before follicular rupture in female pigs (Politis, Srikandakumar et al. 
1990). In addition to time of ovulation/cyclical period, evaluation of areas within the ovary has 
revealed that PAI-1 levels are at their highest immediately prior to ovulation in the centre of the 
ovary where the follicles that are less likely to ovulate reside (smaller follicles including 
primordial and primary follicles) whereas tPA levels at the same stage (in the ovulation 
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process) are highest at the surface of the ovary where pre-ovulatory or Graafian (mature) 
follicles reside (Devin, Johnson et al. 2007) (Figure 5.1). 
 
 
 
Figure 5.1 Internal structure of the ovary and the ovulation process (taken from 
http://catalog.flatworldknowledge.com/bookhub/reader/12013?e=tye_1.0-ch03_s02 Last 
accessed 20/10/2017). 
 
The plasminogen system at an ovarian level is under gonadotropin control, primarily LH 
(Devin, Johnson et al. 2007). Early research showed that each type of plasminogen activator 
involved in the ovulation process is species-specific and cell-specific, with tPA thought to be 
primarily secreted by the GC of rats and pigs in pre-ovulatory/mature follicles and uPA as the 
main plasminogen activator secreted by the GC of mice ovaries just before ovulation (Canipari, 
O'Connell et al. 1987, Liu, Cajander et al. 1987, Politis, Srikandakumar et al. 1990). 
Subsequent studies have shown that both plasminogen activators (PA) are of importance in 
ovulation within a species, however with likely differing actions (Macchione, Epifano et al. 
The Haemostatic System in PCOS  
 
115 | P a g e  
 
2000, Dow, Bakke et al. 2002); tPA is thought to be primarily involved in rupture of the 
follicular wall whereas uPA is thought be involved in the tissue remodeling process and in early 
follicular development (Lafrance, Zhou et al. 1993, Cao, Sahmi et al. 2004). A recent review by 
Liu et al have concluded that the serine protease tPA and inhibitor PAI-1 both play the most 
significant roles in oocyte maturation and in ovulation processes (Liu, Liu et al. 2013). They 
note that differences in PA between species do exist with tPA as the only plasminogen activator 
secreted by rats and monkeys (Rhesus) while uPA as the principal plasminogen activator of 
mice. Secretion of tPA is mainly from GC and the oocyte (of rats and mice) while PAI-1 
predominantly form follicular walls (theca cells, TC) (Liu, Liu et al. 2013). In the rat only tPA 
and PAI-1 are under gonadotropin control at an ovarian level, and not uPA (Liu, Liu et al. 
2013). Both a cell-specific and time-dependent response are noted in the rat ovary in expression 
of mRNA and protein levels of tPA and PAI-1, including the area of the ovary where these 
markers are expressed. An overall proteolytic activity just prior to ovulation following an 
increase in tPA and decrease in regulator PAI-1 (both mRNA and protein levels) localized at 
the surface of the ovary was observed (Liu, Liu et al. 2013). Blocking tPA action in rats, 
following administration of α2 antiplasmin, significantly reduces ovulation in this species 
(Tsafriri, Bicsak et al. 1989). In mice however the blocking effects of either tPA or uPA alone 
do not significantly impact ovulation, and only when both plasminogen activators are lost, mice 
display reduced ovulation outcomes (through the reduced fertility rates noted)(Leonardsson, 
Peng et al. 1995). 
The importance of the plasminogen system has also been noted in the regulation of oocyte 
maturation and not just in follicular wall degeneration (Liu, Liu et al. 2013). tPA mRNA is 
secreted by GC of developing follicles however this nuclear product cannot be translated to its 
protein form due to the effects of GC secreted inhibin subunits. It is only when the follicles 
approach ovulation, following a LH surge, inhibin levels decrease and the translation of tPA 
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mRNA occurs. Following the production of tPA protein, germinal vesicle breakdown follows 
to allow the oocyte to resume meiosis (Liu, Liu et al. 2013). It has also been noted that tPA 
plays a role in oocyte release by its effects on the cumulus oophorus and assisting in 
detachment of this from the stratum granulosum prior to ovulation in both rats and mice (Liu 
and Hsueh 1987, Liu, Liu et al. 2013). Research in this area however is still unclear and 
requires further investigation.   
Studies in humans have identified the presence of tPA in GC and within the FF and PAI-1 also 
in TC (Beers 1975, Piquette, Crabtree et al. 1993, Atiomo, Hilton et al. 2000). Studies that have 
evaluated these fibrinolytic/proteolytic system markers and inhibitors within the PCOS ovaries 
in either humans or in animal models are scarce. Ambekar et al found that plasminogen is 
degraded within the FF of the ovary in women with PCOS (Ambekar, Kelkar et al. 2015). 
Atiomo et al, using IHC, found that there was no significant difference in PAI-1 antigen levels 
within the ovaries of PCOS women and controls (Atiomo, Hilton et al. 2000). Their sample size 
however was quite small and the women from whom the samples were taken were at various 
stages of the menstrual cycle. In contrast, Devin et al compared ovarian tissue from women 
with PCOS and unaffected women’s ovaries and found PAI-1 to be prevalent in the PCOS 
ovary but lacking in normal ovaries (Devin, Johnson et al. 2007). They also performed a small 
sub-study on transgenic female mice which constitutively secrete PAI-1 and found the latter to 
contain many large cystic structures within their ovaries and had plasma testosterone levels 
nearly twice as high as observed in control mice (Devin, Johnson et al. 2007). These 
researchers did not evaluate metabolic markers in these mice however Ma et al showed that 
mice which lacked PAI-1, unlike their wild-type counterparts, did not go on to develop obesity 
or IR despite being on a high fat/high carbohydrate diet(Ma, Mao et al. 2004).  
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While PAI-1 is believed to play a physiological role within the ovary in preventing ovulation of 
immature follicles, persistent elevation of this fibrinolytic/proteolytic inhibitor, as observed in 
the plasma of women with PCOS, may potentially contribute to a lack of ovulation. By 
preventing conversion of plasminogen to active plasmin, these high PAI-1 levels will in turn 
prevent follicular wall breakdown of mature pre-ovulatory follicles, the result of which may 
ultimately give rise to the ovarian architecture currently observed in the ovaries of women with 
PCOS. Additionally, the inhibitory effects of PAI-1 on tPA may prevent the latter in 
participating in oocyte maturation events.  
This study (Chapter 5) is the first, that I am aware of, that comprehensively evaluates the 
fibrinolytic/proteolytic system in the PCOS ovary. In this study the expression of 
fibrinolytic/proteolytic markers tPA, uPA, plasminogen, plasminogen/plasmin and regulator 
PAI-1 were investigated in control and PCOS mouse ovaries to ascertain the presence and 
distribution of these markers in these tissues. Experiments described in this chapter aimed to 
identify if these markers may potentially play a role in ovulation and folliculogenesis processes 
and if these processes are disturbed in the PCOS ovaries following observations of aberrations 
or differences in normal levels and/or distributions of these markers in the tissues assessed. As 
PCOS is the leading cause of anovulatory infertility in women in many countries, research into 
this area could potentially provide significant breakthrough as well as support further study into 
the infertility treatment options for women with this very complex and common disorder.  
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5.2 My role 
Chapter 5 is based on the results obtained from an observational study using an animal model 
assessing the fibrinolytic/proteolytic markers plasminogen, plasminogen/plasmin, tPA, uPA 
and PAI-1 in PCOS and control mice ovaries. I initiated a collaboration with Dr Kirsty Walters 
(School of Women’s & Children’s Health, University of New South Wales, Sydney) who 
kindly provided me with paraffin-embedded ovarian tissues from PCOS and control mice. I 
researched appropriate methods for preparation and set these up at RMIT in collaboration with 
Assoc Prof Ian Darby and Dr Dodie Pouniotis. I prepared the required sections from six PCOS 
and six control mice ovaries. I immunohistochemically stained these sections for markers of 
interest (plasminogen, plasminogen/plasmin, tPA, uPA and PAI-1) once I completed any 
method validation and optimisation steps. I then completed training on the Olympus 
Microscope and Slide Scanner (Olympus VS-ASW 2.9, Tokyo, Japan) and was able to scan the 
slides of interest. Further to receiving training on the Olympus cellSense software (Olympus 
cellSense Dimension Desktop 1.16, Tokyo, Japan) I completed image analyses of slides of 
interest once I was competent in this method, which included performing a number of 
troubleshooting requirements. I was responsible for the initial selection of consumables and all 
reagents required for the study and advised my supervisor of the ordering requirements (please 
refer to the Materials and Methods section of the submitted manuscript on the following pages 
for the sources of consumables). I statistically analysed and interpreted the data (following 
consultation with the biostatistician) and wrote the manuscript which has been submitted for 
publication to Biology of Reproduction (manuscript number: BIOLRE-2018-0123). As a result 
of my contribution I am first author on this manuscript.  
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ABSTRACT 
The fibrinolytic system and its relevant inhibitors play a number of roles, apart from their 
function in blood haemostasis, namely in ovulation. Plasminogen is converted to active plasmin 
at the time of follicular rupture through a decrease in plasminogen activator inhibitor-1 (PAI-1) 
and an increase in plasminogen activators. Oligo-/anovulation and follicle arrest are key 
characteristics of PCOS, but few studies have evaluated fibrinolytic/proteolytic markers within 
human PCOS ovaries or PCOS animal models. We used a PCOS mouse model to investigate 
and compare the presence and distribution of fibrinolytic/proteolytic markers plasminogen, 
plasminogen/plasmin, tissue plasminogen activator (tPA), urokinase plasminogen activator 
(uPA) and inhibitor PAI-1 in PCOS and control ovaries. A hyperandrogenised PCOS mouse 
model was used that mimics a breadth of ovarian, endocrine and metabolic features of the 
human condition. Immunohistochemical examination revealed differences in the ovarian 
distribution of PAI-1 that was localised throughout the PCOS ovary unlike peripheral 
distribution of controls and plasminogen that presented in small follicles only in PCOS ovaries 
and not in small follicles of control ovaries. While no differences were noted in the overall 
expression (mean total percentage and mean colour intensity) of ovarian staining of markers 
assessed, our findings show a potential role for the plasminogen system in both the 
physiological mouse ovary and in PCOS. Further studies evaluating these markers at different 
time-points of ovulation may help to further clarify both physiological and potential 
pathological actions these markers play in ovulation processes distorted in PCOS.  
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INTRODUCTION 
Polycystic Ovary Syndrome (PCOS) is a common condition, affecting 12-18% of reproductive 
aged women and is diagnosed based on ovulatory and menstrual disturbance, 
hyperandrogenism and polycystic appearance of ovaries on ultrasound (The Rotterdam 
ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004, March, Moore et al. 
2010, Teede, Misso et al. 2011, Yildiz, Bozdag et al. 2012). Women with PCOS have increased 
risk for cardiovascular disease (CVD) and venous thromboembolism (VTE) likely relating to 
the aberrant metabolic features and high BMI, frequently present in these females, but also to 
the recently identified abnormal haemostatic and fibrinolytic systems (Burchall, Linden et al. 
2011, Burchall, Piva et al. 2016). A likely hypofibrinolytic state is present in women with 
PCOS, relating to increased plasminogen activator inhibitor 1 (PAI-1) which prevents 
conversion of the pro-enzyme plasminogen to its active form of plasmin (Burchall, Piva et al. 
2016). The fibrinolytic system and its inhibitors play a number of roles, apart from their 
function in blood haemostasis and thrombosis. Plasmin has been detected in both the follicular 
fluid (FF) and granulosa cells (GC) of ovarian follicles at the time of or just before rupture in 
porcine models. The study suggested that plasminogen is converted to functional plasmin at the 
time of follicular rupture. This is achieved following a decrease in PAI-1 and an increase in 
plasminogen activators (PA) observed just before follicular rupture in female pigs (Politis, 
Srikandakumar et al. 1990).    PAI-1 levels are at their highest immediately prior to ovulation in 
the centre of the ovary where immature follicles reside whereas tissue plasminogen activator 
(tPA) at the same stage is highest at the surface where pre-ovulatory follicles are localised 
(Devin, Johnson et al. 2007). Both plasminogen activators tPA and uPA were believed to be 
important in ovulation within a species, though with likely differing actions (Macchione, 
Epifano et al. 2000, Dow, Bakke et al. 2002). A recent review by Liu et al concluded that the 
serine protease tPA and inhibitor PAI-1 play the most significant role in oocyte maturation and 
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in ovulation processes (Liu, Liu et al. 2013). They note however that differences in 
plasminogen activators between species do exist with tPA as the only plasminogen activator 
secreted by the GC and oocytes of rats while uPA as the principal plasminogen activator 
secreted by these same cells in mice. Both a cell-specific and time-dependent response are 
noted in the expression of both tPA and PAI-1, with the latter predominantly expressed by the 
theca cells (TC) of follicular walls in the rat ovary. Liu et al confirmed that literature to date 
notes an overall proteolytic activity just prior to ovulation following an increase in tPA and 
decrease in regulator PAI-1 at the surface of the ovary (Liu, Liu et al. 2013). The importance of 
the plasminogen system has also been noted in oocyte maturation and release (Liu, Liu et al. 
2013).  
 Ambekar et al found that plasminogen is degraded within the FF of ovaries in women with 
PCOS (Ambekar, Kelkar et al. 2015). However Atiomo et al did not find a significant 
difference in PAI-1 antigen concentrations within the ovaries of PCOS women compared to 
controls (Atiomo, Hilton et al. 2000). Both studies however included small sample sizes. In 
contrast, Devin et al found PAI-1 to be prevalent in the PCOS ovary but not in non-PCOS 
ovaries (Devin, Johnson et al. 2007). They also performed a small sub-study on transgenic 
female mice which constitutively secrete a stable variant of active human PAI-1 and found the 
latter to contain many large cystic structures within their ovaries and had plasma testosterone 
levels nearly twice as high as in control mice, concluding that overexpression of PAI-1 
promotes the development of PCO in female mice. These researchers did not evaluate 
metabolic or fibrinolytic markers in these mice. However Ma et al showed that mice which 
lacked PAI-1, unlike their wild type counterparts, did not go on to develop obesity and insulin 
resistance, which are key clinical features of PCOS, despite being on a high fat/high 
carbohydrate diet (Ma, Mao et al. 2004).While PAI-1 is believed to play a physiological role 
within the ovary in preventing ovulation of immature central follicles, persistent elevation of 
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the fibrinolytic/proteolytic inhibitor, as is noted in the plasma of women with PCOS, may 
potentially contribute to a lack of ovulation. PAI-1 may prevent follicular wall breakdown of 
more mature pre-ovulatory follicles and may contribute to the ovarian architecture currently 
observed in the ovaries of women with PCOS. PCOS is also a leading cause of infertility 
(Homburg 2003, Azziz, Carmina et al. 2016). Oligo-/anovulation and follicle arrest are key 
characteristics of PCOS, associated with infertility in this group of women, with the exact 
mechanisms driving this still as yet unclear (Pierre, Peigne et al. 2013). In this context, we 
aimed to investigate and compare the presence and distribution of fibrinolytic/proteolytic 
markers plasminogen, plasmin, tPA and uPA and inhibitor PAI-1 in control and PCOS ovaries. 
We used a PCOS mouse model treated with  dihydrotestosterone (DHT) that display extensive 
ovarian, endocrine and metabolic features of humans affected by PCOS including oligo- or 
anovulation, irregular menstrual cycles, polycystic ovaries, obesity and dislipidaemia. We 
hypothesized that all fibrinolytic/proteolytic markers investigated in this study will be detected 
in both the PCOS and control mice ovaries, however they will vary in their expression and 
distribution within the tissues. In general PAI-1 expression will be elevated in the PCOS mouse 
ovaries compared to that of controls and this marker will be distributed throughout the tissue, 
however in controls it will be localised mainly centrally. The ovarian expression and 
distribution of PA in PCOS and control mice will be similar, but differences may be noted for 
plasmin/plasminogen between the two experimental models. 
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MATERIALS & METHODS 
Mice 
As previously reported, the mice used in this study were maintained under standard housing 
conditions (ad libitum access to food and water in a temperature- and humidity controlled, 12-
hour light cycle environment) at the ANZAC Research Institute [Concord, Australia] 
(Caldwell, Middleton et al. 2014). All mice had a wild-type AR genotype and were taken from 
a colony used to generate AR-knockout mice (Walters, Allan et al. 2007, Simanainen, Gao et 
al. 2012). This colony has been backcrossed onto a C57Bl/6J background for at least 10 
generations prior to use in experiments. In all experiments littermate controls were used. All 
procedures were performed under ketamine/xylazine anesthesia. All procedures were approved 
by the Sydney Local Health District Animal Welfare Committee within NHMRC guidelines for 
animal experimentation (Caldwell, Middleton et al. 2014).  
 
Development of PCOS mouse model 
The PCOS mice were generated by implanting female mice with 1 cm SILASTIC brand 
implant (id, 1.47 mm; od, 1.95 mm, Dow Corning Corp, catalog no. 508-006) containing 
approx. 10 mg DHT at 21 days of age and for a period of 90 days (Caldwell, Middleton et al. 
2014). Controls were administered a blank (oil) 1cm SILASTIC implants also at 21days and for 
the same time period as PCOS mice. The experimental strategy chosen to generate our PCOS 
mice was based on our previous study where we identified the optimal approach for 
experimental PCOS studies using a mouse model (Caldwell, Middleton et al. 2014). Mice were 
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collected after 13 weeks of drug administration (control, n = 8; DHT, n = 9) when the mice 
were 16 weeks of age (Caldwell, Middleton et al. 2014). 
Assessment of Estrous Cycle  
The stage of the estrous cycle of mice was identified on a daily basis using light microscopy 
examination of vaginal epithelial cell smears, as previously described (Caldwell, Middleton et 
al. 2014). The stage of the estrous cycle was determined based on the presence or absence of 
leukocytes, cornified epithelial cells, and nucleated epithelial cells. Proestrous was 
characterized by the presence of mostly nucleated and some cornified epithelial cells; at the 
estrous stage mostly cornified epithelial cells were present; at metestrus both cornified 
epithelial cells and leukocytes were present; and at diestrus primarily leukocytes were visible 
(Caldwell, Middleton et al. 2014). Mice were anesthetized (at the diestrus stage of the estrous 
cycle of control mice & stage of cycle was unascertainable for PCOS mice as these mice did 
not cycle) using ketamine/xylazine and the ovaries removed.  
 
Collection and processing of ovaries  
Ovaries were weighed and fixed in 4% paraformaldehyde, stored at 4oC overnight after which 
they were put into 70% alcohol (Caldwell, Middleton et al. 2014).  
The present study was completed based on biobanked ovarian tissue samples from control and 
PCOS mice from a prior study (Caldwell, Middleton et al. 2014). Data on body weight/fat, 
metabolic (cholesterol, triglycerides, insulin tolerance test), hormonal (FSH, LH, testosterone) 
and reproductive/ovarian parameters have been previously published (Caldwell, Middleton et 
al. 2014).  
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Paraffin-wax embedded ovarian tissue from the DHT induced PCOS mice and control mice 
was sectioned at 4 μm thickness and mounted onto 3-aininopropyltricttiosilane-coated glass 
slides, then dried overnight in a 50°C incubator or incubated at 60°C for 2 hours. The rabbit 
antibodies used for the study were directed towards the fibrinolytic/proteolytic markers and 
inhibitor of interest.  
Expression of PAI-1, tPA, uPA, plasminogen and plasmin by immunohistochemistry 
We used immunohistochemical detection of PAI-1, tPA, uPA, plasminogen/plasmin and 
plasminogen only in sectioned tissue of both PCOS and control mice. We were unable to 
identify a plasmin only anybody. Immunohistochemistry (IHC) was initially performed on 
sections of normal mouse tissue known to contain PAI-1, tPA, uPA, plasmin and plasminogen; 
namely liver for PAI-1, plasminogen/plasmin and plasminogen only, brain for tPA and kidney 
for uPA (positive control tissues) to determine ideal working conditions. A negative control 
was also tested with each marker by omitting to add the primary antibody. PCOS and control 
sections were stained simultaneously for each marker in order to avoid variability due to 
staining techniques. Commercially available primary antibodies that have been shown to work 
in IHC applications on paraffin-embedded sections (IHC-P) were used for all markers with the 
exception of the plasminogen only antibody that was shown to work in immunocytochemistry 
techniques and it was hypothesized that it would also work in IHC. We confirmed this through 
initial IHC staining of positive and negative controls followed by PCOS and control ovarian 
tissue. 
Slides were deparaffinised in xylene (thrice for 5 min) and rehydrated in graded alcohol (100%, 
100%, 70%). Antigen retrieval was performed in a pressure cooker containing sodium citrate 
buffer (pH 6.0) for 20 min for all markers except for PAI-1 where only 10 min incubation was 
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used and uPA where TrisEDTA buffer (pH 9.0) was used instead of sodium citrate. 
Endogenous peroxide activity was quenched by 3% H2O2 in water for 15 min. Non-specific 
binding was reduced using 1% normal goat serum (ABC Kit VECTASIN). The slides were 
incubated with the primary antibody at room temperature for either 90 min for PAI-1 (rabbit 
polyclonal antibody to mouse PAI-1, ABCAM: ab28207) (1:250), uPA (rabbit monoclonal 
antibody to mouse uPA, ABCAM:ab133563) (1:150), tPA (rabbit polyclonal antibody to 
mouse tPA, ABCAM: ab28208) (1:200) and plasminogen/plasmin antibodies (rabbit polyclonal 
antibody to mouse plasminogen/plasmin, Novus Biologicals: NBP2-19859) (1:300) or 
overnight at 4oC for the plasminogen only antibody (rabbit polyclonal antibody to mouse 
plasminogen, Novus Biologicals: NB300-544)  (1:100). Slides were then incubated with the 
secondary antibody (ABC Kit VECTASIN Anti-rabbit IgG biotinylated, affinity purified     
anti-immunoglobulin) for 30 min for all antibodies except tPA where this step was omitted (as 
the primary antibody to tPA was biotinylated). 3,3’-diaminobenzidene, DAB (Vector 
ImmPACT DAB) was used as a chromagen for 120-180 sec and haematoxylin was used for 
counterstaining.  
Image analysis 
Sections were scanned into digital format using an Olympus Microscope and Slide Scanner 
(Olympus VS-ASW 2.9, Tokyo, Japan) keeping the (light) exposure time constant for all slides 
(930 μs). Digital image analysis and processing of each scanned slide was performed using 
Olympus cellSens software (Olympus cellSens Dimension Desktop 1.16, Tokyo, Japan), Count 
& Measure functionality that allows selection of a region of interest and cell/region counting 
capabilities. Intensity analysis was used to determine intensity of (brown) staining in each of 
the sections. Positive thresholds (of intensity of staining) were set for each marker on the 
positive control tissues. The positive thresholds for each marker were then applied to the 
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negative control tissues to ensure negative/no detection of staining for the thresholds set. 
Mouse PCOS and control ovarian tissues were evaluated with the set positive intensity 
threshold of staining of each marker. The whole ovary for both PCOS and controls was selected 
as the region of interest (ROI). Overall ovarian staining (Sum Area, μm²), percentage of 
ovarian staining (Area Fraction ROI, %) and intensity of this staining (Mean Colour Intensity) 
was investigated and compared in PCOS and control ovaries. Sections were also examined and 
the distribution of staining in the ovary (PCOS or control) for each marker was determined. The 
small follicles described typically represent primordial and primary follicles while the large 
follicles include secondary and Graafian follicles   
Sections were examined and characterized by two operators blinded to the identity of the 
ovarian sample/tissue type. 
Statistics 
Image analysis parameters are presented as mean values ±SD. Statistical analysis was 
performed using SPSS for Windows 22.0 software (SPSS, Inc., Chicago, USA) with statistical 
significance p ≤0.05. Data were assessed for normality and log transformed where appropriate. 
Results are presented for a total of 12 ovarian sections/mice ovaries (Controls = 6 ovarian 
sections/mice ovaries & PCOS = 6 ovarian sections/mice ovaries). Differences between PCOS 
and control IHC staining for all markers were assessed using the student’s t test for normally 
distributed data and the Wilcoxon-Mann Whitney test for non-normally distributed data. 
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RESULTS 
As previously published, PCOS mice have DHT concentrations 8-fold higher than that of 
control mice with the former having a mean ± SEM of 1.64 ± 0.32 ng/mL compared to the 
latter of 0.19 ± 0.07 ng/mL (p<0.05) (Caldwell, Middleton et al. 2014).  
Localisation of Fibrinolytic/Proteolytic markers in murine PCOS and Control ovaries 
Expression and localization of PAI-1, tPA, uPA, plasminogen/plasmin and plasminogen only in 
both DHT postnatally inducted PCOS and control murine ovaries was investigated. In the 
control ovaries, PAI-1 was predominantly found in the GC, with highest expression present in 
large follicles located mainly in the periphery of the ovary (Table 1 & Figure 1). The marker 
was also present in the FF and in the stroma with only scant amounts in the small (central) 
follicles and TC. In the PCOS ovaries, PAI-1 was localised throughout the ovary. Similar to 
controls, it was also abundant in the GC, and noted in the FF, stroma and large follicles with 
low amounts noted in the small follicles and TC of PCOS ovaries. 
uPA was present mainly in the periphery of control ovaries as well as in the stroma and GC 
(Table 1 & Figure 2). This marker was also detected in large and some in small follicles but 
only in scant amounts in the TC and FF. A similar pattern was observed in the PCOS ovaries, 
where uPA was predominantly present in the periphery; it was abundant in the GC, present in 
the stoma (mainly in the centre of the ovary), in the large and small follicles with little amounts 
observed in the TC and FF. 
In general tPA was not observed in either the PCOS or control ovaries (Table 1 & Figure 3), 
light staining was noted in the centre of the control ovaries and the stroma, small follicles and 
GC.  
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As there was not a specific plasmin antibody that could be used for IHC staining of the ovaries, 
an antibody which detected both plasminogen/plasmin as well as one which only detected 
plasminogen was used. Differences in the staining between these two antibodies would be most 
likely due to the expression of plasmin itself. Plasminogen/plasmin (NBP2-19859) was present 
mainly in follicles in the periphery of the control ovaries, with lower levels of staining observed 
in central follicles (Table 1 & Figure 4). It was present in abundance in GC and FF and also in 
the stroma. Low levels were detected in blood vessels as well as in the antrum and TC of 
control ovaries. In the PCOS ovaries plasminogen/plasmin was also mainly observed in the 
periphery with a similar pattern of distribution in the GC, FF, stroma, large follicles, antrum, 
blood vessels and TC to that seen in controls. 
The plasminogen antibody NB300-544 only detects plasminogen but not plasmin (Table 1 & 
Figure 5). Plasminogen was detected throughout the ovaries of controls, mainly present in the 
GC and FF. Its presence was detected also in large follicles and sometimes also noted in TC; 
low levels were observed in small follicles, the stroma, antrum and cumulus oophorus of 
control ovaries. In the PCOS ovaries plasminogen was abundantly present in the FF, noted in 
the TC and GC, as well as in small and large follicles, with low levels in the stroma. 
IHC comparisons of fibrinolytic/proteolytic markers in murine PCOS versus control ovaries 
It is well accepted that in human PCOS ovaries are generally larger in size/volume in 
comparison to control ovaries. We noted a significant difference in the average area ROI 
(average ovarian size) between PCOS and control mice ovarian sections (p=0.01). As a result 
of this we then investigated the % of staining of the ovaries in PCOS and controls (Area 
Fraction ROI) of each marker. Overall we did not observe any significant difference in the 
staining for any of the 5 markers evaluated for either mean total area of ovarian IHC staining 
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(Sum Area), Area Fraction ROI or average colour intensity of overall ovarian staining (Mean 
Colour Intensity Value) between PCOS and control ovaries (Table 2). 
 
DISCUSSION 
This is the first study that has comprehensively looked into the expression and distribution of 
fibrinolytic/proteolytic markers and the plasminogen system in the polycystic ovary. 
We observed that four (PAI-1, uPA, plasminogen/plasmin, plasminogen only) out of the five 
markers assessed were expressed in both the PCOS and control mouse ovaries. The exception 
being tPA which was observed in low levels in controls and absent in PCOS mouse ovaries. 
This agrees with that seen in early literature where each type of plasminogen activator involved 
in the ovulation process is species-specific, where uPA is the main plasminogen activator 
secreted by the GC of healthy mice ovaries just before ovulation while tPA is absent (it is 
thought to be primarily secreted by the same cells in pre-ovulatory follicles in rats and pigs) 
(Canipari, O'Connell et al. 1987, Liu, Cajander et al. 1987, Politis, Srikandakumar et al. 1990). 
However, it should be noted that the stage of the oestrous cycle at which the mice were 
assessed may have affected the outcomes, as our control mice were at the diestrus stage of this 
cycle, with few/little presence of pre-ovulatory/large follicles. Our novel data has evaluated the 
presence and distribution of tPA in the PCOS mouse ovary and demonstrates the presence and 
potential role of four of the fibrinolytic/proteolytic markers and of the plasminogen system in 
physiological and/or pathological actions within the ovaries of healthy control mice, and also in 
PCOS mice models, noting the lack of tPA involvement (at this stage of the oestrous cycle) in 
both groups of mice.   
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In the control ovary PAI-1 was predominantly observed in the GC, but also present in large 
follicles mainly in the periphery of the ovary as well as in FF and in the stroma with only low 
levels noted in the small (central) follicles and TC. In the rat, the TC are predominantly 
responsible for the production of PAI-1 with no synthesis from the oocyte (into the FF); the GC 
may also express PAI-1 however this will correlate with the stage of the ovulation cycle to 
ensure appropriate proteolytic (plasmin) activity with each stage (Liu, Peng et al. 1991, Liu, 
Liu et al. 2013). In our study, at the diestrus stage of the cycle, the GC seem to be involved in 
the production of PAI-1 in mice. In prior studies in pigs and rats the distribution of PAI-1 
immediately prior to ovulation is lowest in peripheral/large follicles and highest in small/central 
follicles to assist in ovulation and follicular wall rupture of mature follicles (Liu, Liu et al. 
1997, Devin, Johnson et al. 2007). As the control mice in our study were in the diestrus stage of 
the cycle a different pattern was noted, which may be related to differential proteolytic needs at 
this stage of the cycle (i.e. less needs for high plasmin activity) or the differences noted may be 
related to inter-species differences. If ovulation/fertilization does not take place, PAI-1 levels 
regress, leaving an excess of plasminogen activators to ensure the formation and maintenance 
of the corpus luteum to assist with tissue remodeling processes to form luteal tissues under the 
control of the plasminogen system (Liu, Liu et al. 1997, Devin, Johnson et al. 2007). In the 
PCOS ovary PAI-1 was found throughout the ovary unlike the peripheral distribution observed 
in the controls. It was abundant in the GC, and noted in FF, stroma and large follicles with trace 
amounts in the small follicles and TC. This pattern of distribution noted for PCOS mice may 
relate to the acyclical nature of these mice and the presence of predominantly ‘arrested’ 
follicles that do not go on to ovulate. As PAI-1 is present in follicles approaching ovulation, 
and its levels drop immediately prior to ovulation in pre-ovulatory follicles, even distribution of 
PAI-1 in ovaries of PCOS mice may relate to the presence of follicles in various stages of 
development along with a reduced number of large/pre-ovulatory follicles. Our results are 
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similar to that reported by Devin et al who assessed transgenic PAI-1 overexpressing mice that 
went on to develop multicystic ovaries, in contrast to the wild-type controls (Devin, Johnson et 
al. 2007). In this study PAI-1 was abundant throughout the ovaries of the transgenic mice, and 
highly expressed in the GC of developing follicles, thickened tunica and cyst lining and in the 
hypertrophied theca (interstitium). These researchers also noted little evidence of ovulation in 
the PAI-1 overexpressing transgenic female mice, in comparison to their wild-type 
counterparts, where the various stages of follicular development and the corpora lutea could 
rarely be identified (Devin, Johnson et al. 2007). Atiomo et al observed the presence of PAI-1 
in the granulosa and theca cell compartments of both control and PCOS ovaries with weak 
expression in endothelial cells and serosal surface of humans (Atiomo, Hilton et al. 2000). 
Devin et al observed PAI-1 to be localized on the GC lining cystic structures and in atretic 
follicles and not detected in the TC, stroma, corpora lutea or corpora albicans of females with 
PCOS and was absent or observed in scant amounts in human controls (Devin, Johnson et al. 
2007). Neither research groups stated the stage of the oestrous cycle of control women.  
We selected the whole ovary, as the region of interest when completing image analysis 
investigations and comparisons between PCOS and controls for all five markers evaluated, as 
there have been few or no published studies assessing the plasminogen system in the PCOS 
ovary, in order to investigate if this system, all relevant markers part thereof, is expressed, in 
general, in the PCOS mouse ovary. When we compared the mean total amount of ovarian IHC 
staining, the average intensity of IHC staining and the mean total percentage of ovarian IHC 
staining for PAI-1in PCOS and controls, we found no statistically significant differences for 
these measurements between the two groups. This however does not exclude a potential 
difference in the expression of the marker between PCOS and controls. However, our results 
are consistent with the study by Atiomo et at that also noted overall more PAI-1 was detected 
in PCOS but not statistically different to controls (Atiomo, Hilton et al. 2000).  
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We noted similar patterns of distribution of uPA in PCOS and controls with the marker being 
predominantly present in the periphery and in the GC and stroma of both control and PCOS 
ovaries. It was observed in large and small follicles and some also detected in FF and TC in 
both ovaries. No significant differences in the mean total amount of ovarian IHC staining, the 
average intensity of IHC staining and the mean total percentage of ovarian IHC staining were 
noted for uPA for these two groups. Here we present novel data on the presence and 
distribution of uPA in the PCOS mouse ovary and demonstrate the presence and potential role 
of this plasminogen activator in normal physiological folliculogenesis and tissue remodeling 
processes in mouse ovaries; we also demonstrate no distorted presence/distribution in PCOS. 
Under normal physiological function, uPA (and other plasminogen activators) are thought to 
play a role in the formation and maintenance of the corpus luteum and tissue remodeling 
processes post-ovulation in rhesus monkeys and may do so in mice as well (Liu, Liu et al. 
1997, Liu, Feng et al. 2003, Devin, Johnson et al. 2007).  
A similar pattern of distribution of the plasminogen antibody used in the study (which does not 
distinguish between plasminogen and active plasmin), was noted in PCOS and control ovaries. 
Plasminogen/active plasmin was predominantly present in the peripheral follicles of controls 
and in the periphery of PCOS ovaries. A similar pattern of distribution of this marker was noted 
for other remaining ovarian structures assessed between PCOS and controls. When we used the 
plasminogen-specific antibody we observed this to be expressed throughout the control ovaries 
with strong staining noted in the FF and also observed in the GC and large follicles of both 
control and PCOS ovaries. TC and small follicles of PCOS ovaries seem to express 
plasminogen however this was only sometimes observed or noted in low levels in controls.  
No significant differences were noted between PCOS and controls for mean total amount of 
IHC staining, the average intensity of IHC staining and the mean total percentage of ovarian 
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IHC staining for either the plasminogen/active plasmin or plasminogen only antibody. This was 
novel data showing plasminogen and/or plasmin levels in mice ovaries. In humans, Ambekar et 
al noted that plasminogen was degraded in the FF of the ovary in women with PCOS 
(Ambekar, Kelkar et al. 2015). While we had hypothesized that the differences in staining 
between the plasminogen/active plasmin and plasminogen only antibodies would reveal the 
activity of plasmin only in the ovarian tissues, we actually noted overall stronger ovarian 
staining with the latter when compared to the former antibody. This may be related to 
differences in the activity of each antibody type to its antigen/s of interest. We therefore cannot 
identify and comment on specific plasmin activity and distribution in the PCOS or control 
ovaries and have therefore discussed the activity and distribution of plasminogen and plasmin 
interchangeably/collectively.  
Overall our results demonstrate the expression inferring active role in ovarian function 
including in ovulation and follicular development processes of the plasminogen system in the 
functional mouse ovary and also in PCOS. The results however do not show a statistically 
significant difference between markers assessed in PCOS versus controls for overall ovarian 
expression. These may be related to the small sample size assessed and the stage of the 
ovulation cycle of mice (controls). We noted however differences in the distribution of ovarian 
immunohistochemical staining for PAI-1 and plasminogen only antibodies between PCOS and 
controls indicating potential differences in actions of these markers or underlying causes 
between ovarian physiological and pathological (PCOS) states.   
While not all features of humans affected by PCOS are displayed by the mouse model used, no 
mouse (or other animal) model has been developed to date which does. Additionally as PCOS 
females present with a heterogeneity of clinical features, not all humans affected by the 
syndrome will present with all features listed. The long-term postnally treated DHT PCOS 
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mouse provides the best mouse model for experimental studies of PCOS pathogenesis through 
replicating extensive ovarian (irregular cycles/acyclicity, oligo-/anovulation, multicystic 
ovaries, antral follicle arrest, increased follicle atresia, reduced granulosa and increased theca 
cell layer thickness), endocrine (reduced progesterone and increased DHT) and metabolic  
(obesity, adipocyte hypertrophy, dyslipidaemia and presence of steanosis) features of humans 
affected by the syndrome (Caldwell, Middleton et al. 2014).Strengths of our study include a 
comprehensive analysis of the fibrinolytic/proteolytic markers and the plasminogen system in 
the control and PCOS mouse ovaries, with limited or no studies previously published assessing 
these markers in either physiological or pathological (PCOS) states. Further studies with larger 
samples sizes may further clarify outcomes. Additionally evaluating these 
fibrinolytic/proteolytic markers at different time-points of the oestrous cycle, particularly 
immediately preceding ovulation, or assessing the plasminogen system in individual ovarian 
follicles of varying sizes from small to pre-ovulatory follicles, may help to further clarify 
physiological and any potential pathological roles of these markers in the ovulation process and 
in aberrant folliculogenesis in PCOS. Such studies may significantly improve our 
understanding of this very complex condition as well as assist with treatment options for the 
frequent infertility noted for women with this common syndrome. 
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FIGURE LEGENDS 
Figure 1: Expression of PAI-1 in normal and PCOS mouse ovaries. Representative histological 
images are from normal (control) (A, B) or PCOS ovaries (C, D) stained with an anti-PAI 
antibody. The scale bar represents either 100 μm (A, B & D) or 200 μm (C). 
Figure 2: Expression of uPA in normal and PCOS mouse ovaries. Representative histological 
images are from normal (control) (A,B) or PCOS ovaries (C,D) stained with an anti-uPA 
antibody. The scale bar represents either 200 μm (A), 100 μm (C & D) or 50 μm (B).  
Figure 3: Expression of tPA in normal and PCOS mouse ovaries. Representative histological 
images are from normal (control) (A,B) or PCOS ovaries (C,D) stained with an anti-tPA 
antibody. The scale bar represents either 200 μm (A, C & D) or 100 μm (B).  
Figure 4: Expression of plasminogen/plasmin (NBP2-19859) in normal and PCOS mouse 
ovaries. Representative histological images are from normal (control) (A,B) or PCOS ovaries 
(C,D) stained with an anti-plasminogen/plasmin antibody. The scale bar represents 100 μm.  
Figure 5: Expression of plasminogen (NB300-544) in normal and PCOS mouse ovaries. 
Representative histological images are from normal (control) (A,B) or PCOS ovaries (C,D) 
stained with an anti-plasminogen only antibody. The scale bar represents either 100 μm (A, B 
& C) or 200 μm (D).  
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TABLES 
Table 1: Expression of the plasminogen system in the granulosa and theca cells, large and 
small follicles and general distribution in control and PCOS mice ovaries. 
 Granulosa cells Theca cells Large follicles Small follicles General 
distribution 
 Cont PCOS Cont PCOS Cont PCOS Cont  PCOS Cont PCOS 
PAI-1 + + - - + + - - P T 
tPA - - - - - - - - A A 
uPA + + - - + + + + P P 
Plasminogen
/Plasmin 
+ + - - + + - - P P 
Plasminogen 
only 
+ + +/- + + + - + T T 
‘+’ = expression of marker; ‘-’= marker absent or in low levels. PAI-1, plasminogen activator inhibitor-1; tPA, 
tissue plasminogen activator; uPA, urokinase plasminogen activator; Cont, controls; P, peripheral; C, central; T, 
throughout; A, absent.  
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Table 2: Comparisons of mean total area of ovarian IHC staining (Sum Area), percentage of 
ovary stained (Area Fraction ROI) and average intensity of overall ovarian staining (Mean 
Colour Intensity Value) of markers assessed in PCOS and control mice ovaries.  
Marker PCOS/Cont  Sum Area  
(x103, μm²) 
Area fraction 
ROI (%) 
Mean (Colour) 
Intensity Value 
PAI-1 Controls  281±264 7.86±5.96 178.27±6.79 
 PCOS 323±266 13.90±10.57 177.07±8.40 
tPA Controls  17±22 0.63±0.79 172.90±6.02 
 PCOS 8±10 0.29±0.38 169.73±4.20 
uPA Controls  227±174 7.61±5.72 164.58±6.57 
 PCOS 155±125 6.86±5.37 163.43±4.04 
Plasminogen/Plasmin 
NBP2-19859 
Controls  271±183 7.21±4.09 178.95±3.18 
PCOS 193±79 8.64±3.53 180.70±6.25 
Plasminogen   
NB300-544 
Controls  1,147±1,092 38.93±23.14 165.16±5.09 
PCOS 936±646 41.10±23.38 162.72±8.75 
Mean±SD are represented for all values. PAI-1, plasminogen activator inhibitor-1; tPA, tissue plasminogen 
activator; uPA, urokinase plasminogen activator; ROI, region of interest. 
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 CHAPTER 6: Conclusions and Future Directions 
 
6.1 Final Conclusions 
Relevant discussions and conclusions of the work presented in the body of this thesis have 
been presented in each chapter, centred around published or submitted manuscripts. I will 
conclude with a summary of the original contribution my work has made to the knowledge 
and understanding of the haemostatic system in women with PCOS. I have also incorporated 
future directions, limitations and overall conclusions in separate sections below. 
This thesis comprised a series of related studies that aimed to enhance our understanding of 
the haemostatic system in women with PCOS, including relationships with the commonly 
aberrant hormonal and metabolic systems and also aimed to identify the potential for further 
CV and venous thrombosis risk factors in an already high-risk group. Following a review of 
the literature (Chapters 1 and 2) it was shown that an aberrant primary haemostatic response 
was associated with PCOS, with abnormal platelet activation/function with studies showing 
increased sCD40L (Zwirska-Korczala, Sodowski et al. 2008, Oktem, Ozcimen et al. 2009, 
Kebapcilar, Kebapcilar et al. 2011, El-Mesallamy, Abd El-Razek et al. 2013) and elevated 
MPV (Gursoy, Ertugrul et al. 2006, Kebapcilar, Taner et al. 2009, Cakiroglu, Vural et al. 2016, 
Yilmaz, Duran et al. 2016); also, endothelial dysfunction was noted in females with the 
syndrome, as reflected mainly by elevations in ADMA (Charitidou, Farmakiotis et al. 2008, 
Heutling, Schulz et al. 2008, Ozgurtas, Oktenli et al. 2008, Moran, Hutchison et al. 2009, 
Rajendran, Willoughby et al. 2009, Moran, Cameron et al. 2011, Toulis, Goulis et al. 2011, 
Bayrak, Dursun et al. 2012, Choi, Yang et al. 2012) and PAI-1 (Sampson, Kong et al. 1996, 
Atiomo, Bates et al. 1998, Macut, Micic et al. 2001, Sills, Drews et al. 2003, Diamanti-
Kandarakis, Palioniko et al. 2004, Glueck, Wang et al. 2004, Orio, Palomba et al. 2004, 
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Carmassi, De Negri et al. 2005, Lin and Yongmei 2008, Moran, Hutchison et al. 2009, Oral, 
Mermi et al. 2009, Manneras-Holm, Baghaei et al. 2011, Toulis, Goulis et al. 2011, Koiou, 
Tziomalos et al. 2012, Moran, Noakes et al. 2012, Aziz, Sidelmann et al. 2015, Elci, Kaya et al. 
2017). The potential for an abnormal coagulation or a secondary haemostatic response was also 
suggested with some studies reporting high fibrinogen levels (Atiomo, Bates et al. 1998, 
Erdogan, Karadeniz et al. 2008, Heutling, Schulz et al. 2008, Bagir, Bakiner et al. 2016). 
Increased tPA levels (Kelly, Lyall et al. 2002, Sills, Drews et al. 2003, Lin and Yongmei 2008, 
Lindholm, Bixo et al. 2010), most likely reflecting tPA–PAI-1 complexes, indicating enhanced 
inhibition of fibrinolysis confirmed by studies showing high PAI-1 antigen and/or activity as 
well as some studies showing elevated TAFI levels (Karakurt, Gumus et al. 2008, Oral, Mermi 
et al. 2009, Guldas, Altinkaya et al. 2015). Global haemostatic tests showed increased 
generation of thrombin, through the TG assay (de Mendonca-Louzeiro, Annichino-Bizzacchi et 
al. 2013, Glintborg, Sidelmann et al. 2015), and a reduced fibrinolytic state through a decreased 
GFC (Yildiz, Haznedaroglu et al. 2002, Andiran, Yordam et al. 2005), where further 
detrimental effects on the haemostatic system in women with the syndrome may be observed 
with increased fibrin formation, potential further activation of platelets (and therefore further 
negative outcomes on the primary haemostatic system/response) and a reduced capacity to 
counteract coagulation effects.  
At the time the review was published (2011) it was also noted that many of the existing studies 
were suboptimal and that more robust study designs were needed to accurately evaluate the 
haemostatic system in women with PCOS. This included adequately powered studies, 
participants matched for age, BMI and confounding factors such as relevant medication usage 
(that can affect haemostasis) and assessment for smoking status (Burchall, Linden et al. 2011). 
More recent studies however (completed in the past 5-7 years) have shown improved study 
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protocols in general. The literature evaluating the haemostatic system in PCOS however is still 
limited and heterogeneity in quality and outcome persist (Burchall, Linden et al. 2011, Toulis, 
Goulis et al. 2011) (see Chapter 2). Overall the published review of the literature showed the 
lack of available data that had comprehensively, accurately and systematically evaluated the 
haemostatic system in women with PCOS, including a lack of assessment of global markers of 
haemostatic function, such as the TG test, as well as relevant coagulation factors and 
coagulation markers that evaluate for in vivo haemostatic effects including PF1 & 2 and urinary 
TXM (Burchall, Linden et al. 2011). The literature had therefore failed to adequately explain 
both the true state of the haemostatic system in women with PCOS and the mechanisms by 
which many of the haemostatic effects were noted. This however did reveal a need for further 
research to address these key gaps in our knowledge, potentially also through use of 
interventions that modulate the abnormal hormonal and metabolic features and observation of 
the haemostatic effects/outcomes in these contexts. While existing literature failed to 
adequately assess and address the state of the haemostatic system in women with the syndrome, 
it did however suggest a pro-thrombotic state as a potential CV and venous thrombosis risk. 
This review of the literature was published in a reputable scientific journal to ensure 
dissemination of outcomes to other researchers in the field (Burchall, Linden et al. 2011). 
Building on my extensive literature review, I wanted to address the gaps highlighted. The 
cross-sectional study completed in Chapter 3 aimed for a systematic, comprehensive and 
reliable assessment of the haemostatic system; both pro- and anti-thrombotic markers of 
haemostasis were evaluated as well as markers of global assessment. Markers that assessed 
components of the haemostatic system in women with PCOS were measured including those of 
the primary haemostatic system (through evaluations of principal endothelial function markers 
PAI-1 and ADMA), while secondary haemostasis was evaluated through markers of in vivo 
The Haemostatic System in PCOS  
 
154 
 
coagulation cascade activation and of in vivo mediated thrombosis, namely PF1 & 2. The TG 
test was used as a global marker of haemostasis measurement, which evaluates the net 
coagulation effects following coagulation cascade activation but also accounts for the 
simultaneous effects of coagulation inhibitors. tPA and plasminogen were measured to identify 
the state of the fibrinolytic system and PAI-1 activity was also determined, as a principal 
inhibitor of fibrinolysis. I followed a robust study design, completed pre-study power 
calculations to ensure adequate statistical power, considered factors that could interfere with 
haemostatic function including age, BMI and smoking status and medications that could 
interfere with study outcomes (such as OCP). I also completed relevant correlation studies 
between the haemostatic system markers measured and those of the metabolic (HOMA-IR and 
insulin level) and hormonal (testosterone levels) systems. I explored for potential mechanisms 
of action and relationships between these systems. Further to this, I explored the effects of other 
markers frequently aberrant in PCOS including lipids such as LDL, triglycerides and 
cholesterol as well as assessed for effects of waist circumference on haemostasis and 
endothelial function. 
I noted endothelial dysfunction indicating a potentially aberrant primary haemostatic 
system/response in women with PCOS in comparison to controls, and a further CV risk marker, 
through increased ADMA and PAI-1, regardless of age, BMI, waist circumference or lipid 
profile. I was also able to demonstrated that endothelial dysfunction was related to both the 
aberrant metabolic (HOMA-IR) and hormonal (testosterone levels) systems through regression 
analyses.  No coagulation cascade (secondary haemostasis) abnormalities were noted in women 
with the syndrome compared to controls (including the function/effects of inhibitors of 
coagulation), and no relationships with metabolic factors (IR and insulin levels) and hormone 
relationships. Clear evidence of impaired capacity for fibrinolysis was detected and age, BMI, 
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waist circumferences and the lipid profile did not affect these outcomes. With increased activity 
of inhibitor of fibrinolysis, PAI-1, as well as increased plasminogen (likely arising due to 
reduced conversion to active plasmin), a hypofibrinolytic state arises, with further CV and VTE 
risks. While the reasons for this are somewhat unclear, my research supported potential 
mechanisms driving this hypofibrinolytic state; reduced fibrinolytic effects may be linked, at 
least in part, to abnormal endothelial function with significant relationships noted to the 
aberrant hormonal (hyperandrogenaemia) and metabolic (IR/hyperinsulinaemia) systems. The 
outcomes of this research were published to ensure broad dissemination of these important 
findings (Burchall, Piva et al. 2016). 
Abnormal endothelial function and a hypofibrinolytic capacity was demonstrated in my first 
study (see Chapter 3), and women with PCOS have higher risks for and apparent higher rates of 
CVD and VTE. Additionally, the frequently prescribed management strategies to women with 
PCOS including the OCP present with well accepted risks of VTE in the general population. In 
the second study (Chapter 4) I explored the haemostatic impact of current treatments for PCOS 
to identify if these treatment strategies may exacerbate the cardiovascular and venous 
thrombotic risks noted. OCP have haemostatic effects with a net pro-coagulant outcome for 
those in the general population while metformin some positive haemostatic results, yet neither 
treatment option was adequately explored nor the haemostatic impacts documented in women 
with the syndrome. Furthermore, varying haemostatic and thrombotic effects have been noted 
from use of differing preparations of combined oral contraceptives in the general population 
and therefore it was also important to explore the effects of oestrogen dosage, progesterone 
preparation and use of an anti-androgen component and haemostatic impacts in PCOS.  
In my second study I assessed haemostatic outcomes following commonly prescribed medical 
therapies in women with PCOS, including low oestrogen dose OCP of 20μg EE (combined 
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with a second generation progesterone, levonorgestrel and an anti-androgen, spironolactone), 
higher-dose OCP of 35μg EE (combined with a third generation progestin component, 
cyproterone acetate) or metformin. Correlations between haemostatic markers with hormonal 
and metabolic markers both within and between intervention groups were also explored to 
investigate potential underlying mechanisms of action for the OCP. I noted beneficial effects 
from all interventions on the endothelium, particularly following higher-dose OCP, through a 
reduction in either or both endothelial function markers (PAI-1 and ADMA). Both OCPs 
however demonstrated an aberrant coagulation profile (following increased TG with both 
hormonal treatments as well as an increase in PF1 & 2 levels in the higher-dose group) and a 
hypofibrinolytic state with higher-dose OCP (following observations of increased TAFI 
activity in this group). As increased coagulation and generation of thrombin was noted, this 
may serve to counteract some of the positive effects noted on the primary haemostatic 
system/response, following potential increased activation of platelets by OCPs, as thrombin is a 
powerful platelet agonist (McNicol and Robson 1997). Overall, metformin therapy appeared to 
have beneficial haemostatic effects, a potential improvement in primary haemostasis and no 
(net) effects on coagulation. Potential mechanisms of action included improved endothelial 
function, which is likely related to improved androgen (testosterone) levels with OCP use and 
from a better metabolic (AUC Insulin) profile with metformin administration. Androgens and 
the metabolic profile appear to be able to influence coagulation status in PCOS. When 
comparing the three interventions, metformin had overall favorable haemostatic outcomes and 
may reduce risks of CVD and VTE when compared to both the higher- or low-dose OCP 
therapies. Outcomes of this study were published (Burchall, Piva et al. 2017) in order to better 
inform clinical practice of the haemostatic system effects of common management strategies 
used in women with PCOS.  
The Haemostatic System in PCOS  
 
157 
 
As PCOS is the leading cause of anovulatory infertility and as the fibrinolytic system has 
demonstrated both a fibrinolytic but also a proteolytic role including in a number of ovarian 
functions, the third study (Chapter 5) aimed at investigating the expression and distribution of 
the fibrinolytic/proteolytic markers and the plasminogen system in PCOS and control mouse 
ovaries. A PCOS mouse model (long-term postnally treated DHT) that displayed extensive 
features of humans with this syndrome was used in this study. These mice have been shown to 
provide for the best mouse model for experimental studies of PCOS pathogenesis (Caldwell, 
Middleton et al. 2014). Little or no evidence has been published on the state of the plasminogen 
system in the PCOS ovary in animals or humans and as my earlier investigations demonstrated 
a hypofibrinolytic state in women with the syndrome (see Chapter 3), I aimed to identify if 
these fibrinolytic alterations contributed to the anovulation and ovarian architecture seen in 
PCOS. The results of this study demonstrated involvement of the plasminogen system in both 
the physiological control mouse ovary and in PCOS, and potentially in ovulation and follicular 
development processes. All the fibrinolytic markers (uPA, plasminogen and 
plasminogen/plasmin) and inhibitor (PAI-1) assessed were shown to be expressed in both 
PCOS and control mouse ovaries, except for tPA. While I did not observe any significant 
differences in overall ovarian expression (mean total percentage and mean colour intensity) of 
markers assessed between PCOS and controls, differences were noted in the ovarian 
distribution of PAI-1 (that was localised throughout the PCOS ovary unlike peripheral 
distribution seen in control ovaries) and plasminogen (that presented in small follicles only in 
PCOS but not in these same follicles of control ovaries), indicating potential differences in 
ovarian physiology in PCOS. While further research is still needed in this novel area of study, 
the outcomes from this study provide the foundation for further studies. They enhance our 
understanding of this very complex condition and may assist with therapeutic options for 
anovulation in PCOS. 
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6.2 Limitations 
Whilst these studies have made important contributions to the literature, it must be 
acknowledged that both the first and second study were completed on biobanked plasma 
samples from earlier studies (Meyer, McGrath et al. 2007, Hutchison, Stepto et al. 2011, 
Moran, Strauss et al. 2011, Stepto, Cassar et al. 2013), which addressed different end-points. 
However haemostatic assessment was part of the original study protocols and appropriate 
samples were collected and processed. Original study methods were rigorous and the 
participants well characterized. Additionally these first two studies only assessed one arm of 
the primary haemostatic response, namely endothelial function and could have benefited 
from assessment of platelet functionality/activation studies in this group of women. As only 
platelet-poor plasma (stored frozen at -80oC) was available, it was difficult to complete this 
assessment, as fresh whole blood or platelet-rich plasma (for platelet functional studies), 
serum (for measurement of sCD40L levels) or urine (for TXM analyses) would have been 
required (Paniccia, Priora et al. 2015). Results presented are from cross-sectional studies, 
rather than longitudinal research. Not all markers were measured on all parameters due to 
lack of availability of sufficient plasma for some samples. Differing progestin components 
were used in the second study as part of the combined oral contraceptives as preparations of 
differing oestrogen doses with the same progesterone component were unavailable at the time 
of study.  
Limitations of the final study include a lack of assessment of ovarian plasminogen system 
markers and inhibitors at differing time-points of the oestrous cycle, particularly immediately 
preceding ovulation. Only mouse (control) ovarian tissue at the diestrus stage of the cell cycle 
was available. Evaluation of plasmin in PCOS (and control) ovarian tissue would have 
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greatly assisted in interpretation of outcomes in this final study however this was not possible 
due to lack of a suitable commercial plasmin only antibody.  
 
 
6.3 Key Future Research Goals 
The findings of this thesis have enhanced our knowledge of the haemostatic system in women 
with PCOS, yet they have also unearthed a number of questions and areas for future research 
including a need for further evaluation of the primary haemostatic system platelet functionality 
and potential aberrant activation in females with the syndrome. Insufficient research has been 
completed to date on this branch of the haemostatic system and enhanced platelet aggregability 
may also increase the risk of thrombosis and of CVD. Further studies assessing platelet 
function following use of OCPs (and other common treatments) that pose increased CV or VTE 
risks is also pertinent and should be investigated further, especially considering the frequency 
of use in women with PCOS and the outcomes noted in Chapter 4.  
Due to the heterogeneity of clinical features that females with PCOS can present, four PCOS 
phenotypes are currently described (by the Rotterdam and Androgen Excess Society) including 
(1) Frank PCOS (oligomenorrhoea, hyperandrogenism, and PCO), (2) Ovulatory PCOS 
(hyperandrogenism, PCO, and regular menstrual cycles), (3) Non-PCO PCOS 
(oligomenorrhoea, hyperandrogenism, and normal ovaries) and (4) mild or normoandrogenic 
PCOS (oligomenorrhoea, PCO, and normal androgens) (Clark, Podolski et al. 2014). As the 
prevalence of CV risk varies with different PCOS phenotypes (Tziomalos 2016), studies 
assessing the haemostatic system in women with PCOS using different diagnostic criteria 
(NIH, Rotterdam and AES) should be also be completed to identify if any significant 
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differences are noted in haemostatic outcomes and to determine if the haemostatic system may 
be associated with these differing risks for the four PCOS phenotypes.  
Additionally, as age is an important consideration by clinicians prescribing the OCP, large 
studies should be carried out assessing the haemostatic effects of different OCPs on different 
age groups in women with PCOS, as the studies completed to date assessing these 
pharmacological effects in this group of women are limited and include small sample sizes and 
as increasing age is well known to increase cardiovascular risk. 
Studies comparing haemostatic impacts of common pharmacological treatments such as OCPs 
in women not affected by PCOS versus females with the syndrome should also be undertaken 
as well as comparisons made to women in the general population not on hormonal therapies. 
Such studies are limited and are needed to accurately ascertain the cardiovascular effects and 
risks of these management strategies in women with this syndrome, which are likely to show 
the significant CV and/or VTE risks posed with such therapies in women with PCOS.  
Evaluation of the plasminogen system and relevant inhibitors in the human ovary in PCOS at 
different time points of the menstrual cycle, particularly immediately preceding ovulation, as 
well as evaluation of the markers in different sized ovarian follicles, from small to 
large/Graafian follicles, would also be critical, to review for potential links to aberrant 
ovulation and folliculogenesis. This may help to determine aetiological factors and/or 
pathological pathways contributing to the reduced fertility in females with this syndrome. 
Pregnancy is considered a hypercoagulable state (Shan, Wang et al. 2013) and females with 
PCOS have been observed to have increased risks for pregnancy associated complications, 
including increased rates for miscarriage (Kamalanathan, Sahoo et al. 2013). Additionally, as 
aberrant haemostasis was demonstrated (in Chapter 3), evaluation of haemostatic markers in 
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pregnant females with PCOS, and correlating to infant outcomes, would also be very important 
and should be considered in future research studies. Such studies may help to identify a 
potential for high risk of thrombosis in pregnant females with PCOS and may unravel 
aetiological factors linked to early foetal loss potentially following from placental 
insufficiency. 
 
6.4 Overall Conclusions 
Given the high prevalence of PCOS with strong links to CVD and VTE risk factors, few 
published studies had been completed on the haemostatic system in PCOS. Yet this system is a 
key contributor to cardiovascular and thrombotic outcomes. The findings presented in this 
thesis have made a significant contribution to the understanding of the haemostatic system in 
women with PCOS and demonstrate a potential further CV and venous thrombosis risk factor 
in this already high-risk group, exacerbated by some of the common treatments used. 
Involvement of the fibrinolytic/proteolytic system in the PCOS ovary and in potential aberrant 
ovarian functions has also been shown which may contribute to anovulation and infertility. 
Overall the findings of this thesis have helped improve our understanding of this very complex 
condition and may guide development of future treatments. 
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APPENDIX 1 
Exemption from Ethics Review (Outcome) 
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 APPENDIX 2 
TAFI Activity in PCOS and Controls 
 
Table A2.1 displays the TAFI activity results for PCOS and control participants part of the first 
study (Chapter 3) not included in the final published paper (Burchall, Piva et al. 2016) due to 
the low control (non-PCOS) sample numbers available.  
 
Table A2.1: TAFI activity in PCOS and controls. 
Variable PCOS  
(n=51) 
Non-PCOS (n=17) p-value p-value 
adjusted 
TAFI Activity (%) 
(n=68) 
121.0 (103.0-137.0) 
  
116.0 (99.0-141.5)     0.854 0.720 
Median (interquartile range) and P values from log transformed data. p-value adjusted = p value adjusted for age and BMI. TAFI=thrombin 
activatable fibrinolysis inhibitor.  
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 APPENDIX 3 
 Collaborative Research Agreement and Memorandum of Understanding 
Project title 
Plasminogen System in the PCOS Mouse Ovary: An observational study looking into the 
fibrinolytic/proteolytic markers Plasminogen, Plasmin, tPA, uPA and inhibitor PAI-1 in the ovaries of 
PCOS mice versus ovaries of control mice. 
 
Researchers / investigators 
 
Conception date 
Memorandum drafted and sent to all collaborators for review and appoval on the 1st of June 2016. 
School of Health & 
Biomedical Sciences, RMIT 
University 
MCHRI, SPHPM, 
Monash University 
 
ANZAC Research 
Institute, University 
of Sydney 
 
Robinson Research 
Institute, University 
of Adelaide 
Assoc Prof Terrence Piva 
Mrs Genia Burchall 
Assoc Prof Ian Darby 
 
 
 Prof Helena Teede 
 
Dr Kirsty Walters 
 
 
Prof Ray Rogers 
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Background 
Polycystic Ovarian Syndrome (PCOS) is a condition which affects 12-18% of reproductive aged 
women and is diagnosed based on ovulatory and menstrual disturbance, hyperandrogenism and 
polycystic appearance of ovaries on ultrasound (The Rotterdam ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group 2004, Teede, Misso et al. 2011)(March, Moore et al. 2010, Yildiz, Bozdag 
et al. 2012). PCOS also presents with aberrant metabolic features including hyperinsulinaemia, insulin 
resistance (IR) and dislipidaemia. Women with PCOS have increased risks for cardiovascular disease 
(CVD) and venous thromboembolism (VTE) likely relating to the aberrant metabolic features and high 
BMI as well as an abnormal haemostatic system (Burchall, Piva et al. 2016). A likely hypofibrinolytic 
state is present in women with PCOS, relating to increased plasminogen activator inhibitor 1 (PAI-1) 
which prevents conversion of the pro-enzyme plasminogen to its active form, plasmin (Burchall, Piva 
et al. 2016). The fibrinolytic system components and relevant inhibitors however play a number of 
roles, apart from their function in blood haemostasis and thrombosis. Of importance to research into 
PCOS is their role in the ovulation process.  
 
Plasmin has been detected in both the follicular fluid and granulosa cells of the ovary at the time of or 
just before rupture of the ovarian follicle in porcine models (Politis, Srikandakumar et al. 1990). This 
suggests that plasminogen is converted to plasmin at the time of follicular rupture (ovulation). To 
achieve this increased plasmin activity, a decrease in inhibitor PAI-1 and an increase in plasminogen 
activators (tissue plasminogen activator, tPA and/or urokinase plasminogen activator, uPA) is needed, 
also observed just before follicular rupture in female pigs (Politis, Srikandakumar et al. 1990). In 
addition to time of ovulation/cyclical period, evaluation of areas within the ovary has revealed that    
PAI-1 levels are at their highest immediately prior to ovulation in the centre of the ovary where the 
follicles that are less likely to ovulate reside whereas tPA levels at the same stage (in the ovulation 
The Haemostatic System in PCOS  
 
167 
 
process) are highest at the surface of the ovary where pre-ovulatory or Graafian (mature) follicles reside 
(Devin, Johnson et al. 2007) (Figure A3.1).  
 
 
Figure A3.1 Internal structure of the ovary and the ovulation process (taken from 
http://catalog.flatworldknowledge.com/bookhub/reader/12013?e=tye_1.0-ch03_s02 Last accessed 
25/05/2016). 
 
The plasminogen system at an ovarian level is under gonadotropin control, primarily luteinizing 
hormone (LH) (Devin, Johnson et al. 2007). Early research has shown that each type of plasminogen 
activator involved in the ovulation process is species-specific and cell-specific, with tPA thought to be 
primarily secreted by the granulosa cells of rats and pigs in pre-ovulatory/mature follicles and uPA as 
the main plasminogen activator secreted by the granulosa cells of mice ovaries just before ovulation 
(Canipari, O'Connell et al. 1987, Liu, Cajander et al. 1987, Politis, Srikandakumar et al. 1990) (Figure 
A3.2).  Subsequent studies have shown that both plasminogen activators are of importance in ovulation 
within a species, however with likely differing actions (Macchione, Epifano et al. 2000, Dow, Bakke et 
al. 2002); tPA is thought to be primarily involved in rupture of the follicular wall whereas uPA is 
thought be involved in the tissue remodeling process and in early follicular development (Lafrance, 
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Zhou et al. 1993, Cao, Sahmi et al. 2004). Research in this area however is still unclear and requires 
further investigation.  
 
 
Figure A3.2 Development of ovarian follicles (taken from sugiritama.blogspot.com Last accessed 
25/05/2016) 
 
Studies in humans have identified the presence of tPA in granulosa cells and within the follicular fluid 
and PAI-1 also in theca cells (Beers 1975, Piquette, Crabtree et al. 1993, Atiomo, Hilton et al. 2000). 
Few studies have evaluated these fibrinolytic/proteolytic system markers and inhibitors within the 
PCOS ovaries in either humans or in animal models. Ambekar et al found that plasminogen is degraded 
within the follicular fluid of the ovary in women with PCOS (Ambekar, Kelkar et al. 2015). Atiomo et 
al, using immunohistochemistry (IHC), found that there was no significant difference in PAI-1 antigen 
levels within the ovaries of PCOS women and controls (Atiomo, Hilton et al. 2000). Their sample size 
however was quite small and the women from whom the samples were taken were at various stages of 
the menstrual cycle. In contrast, Devin et al compared ovarian tissue from women with PCOS and 
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unaffected women’s ovaries and found PAI-1 to be prevalent in the PCOS ovary but lacking in normal 
ovaries (Devin, Johnson et al. 2007). They also performed a small sub-study on transgenic female mice 
which constitutively secrete PAI-1 and found the latter to contained many large cystic structures within 
their ovaries and had plasma testosterone levels nearly twice as high as in control mice (Devin, Johnson 
et al. 2007). These researchers did not evaluate metabolic markers in these mice however a paper 
published by Ma et al showed that mice which lacked PAI-1, unlike their wild type counterparts, did 
not go on to develop obesity and insulin resistance despite being on a high fat/high carbohydrate diet 
(Ma, Mao et al. 2004).  
 
While PAI-1 is believed to play a physiological role within the ovary in preventing ovulation of 
immature follicles, persistent elevation of this fibrinolytic/proteolytic inhibitor, as observed in the 
plasma of women with PCOS, may potentially contribute to a lack of ovulation. By preventing 
conversion of plasminogen to active plasmin, the high PAI-1 levels will in turn prevent follicular wall 
breakdown of more mature pre-ovulatory follicles, the result of which may ultimately give rise to the 
ovarian architecture currently observed in the ovaries of women with PCOS. 
 
Objectives and hypotheses 
We aim to investigate the presence and distribution of fibrinolytic/proteolytic markers plasminogen, 
plasmin, tPA and uPA and inhibitor PAI-1 in PCOS ovaries compared to ovaries from control mice. 
We will use dihydrotestosterone (DHT)-treated mice that display extensive ovarian, endocrine and 
metabolic features of humans affected by PCOS including oligo- or anovulation, irregular menstrual 
cycles, polycystic ovaries, obesity and dislipidaemia (Caldwell, Middleton et al. 2014). We also aim to 
correlate the presence/absence of the aforementioned fibrinolytic/proteolytic markers and inhibitors 
within the PCOS and control mouse ovaries with that of hormonal and metabolic markers available for 
the rodents. We hypothesize that PAI-1 is elevated in the PCOS mouse ovary in comparison to controls 
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and the high levels/activity of this marker is distributed throughout the ovary and not restricted to 
immature follicles in the central region of the ovary. In the controls however PAI-1 is restricted to the 
centre of the ovary with scant or no detectable levels/activity in mature pre-ovulatory follicles on the 
surface of the ovary. tPA, uPA and/or plasminogen may show strong staining/presence in both the 
PCOS and control mice, particularly at the surface of the ovary (in pre-ovulatory follicles) however 
plasmin activity should only be evident/significantly increased in the control mice but not in the PCOS 
mice ovarian tissue.  
 
Materials and methods 
The present study will be completed based on bio-banked ovarian tissue samples from control and 
PCOS mice from a prior study lead by Dr Kirsty Walters (Caldwell, Middleton et al. 2014). They have 
published data on metabolic, hormonal and reproductive/ovarian parameters of these mice (Caldwell, 
Middleton et al. 2014). The Sydney Local Health District Animal Welfare Committee approved the 
original study as being within NHMRC guidelines for animal experimentation. The PCOS mice were 
generated by implanting female mice with 1-cm Silastic brand implant (id, 1.47 mm; od, 1.95 mm, 
Dow Corning Corp, catalog no. 508-006) containing approx. 10 mg DHT at 21 days of age. PCOS 
mice displayed DHT levels 8x higher than that of control mice. The stage of the estrous cycle was 
identified on a daily basis using light microscopy examination of vaginal epithelial cell smears, as 
previously described (Caldwell, Middleton et al. 2014). Mice were anesthetized using 
ketamine/xylazine and the ovaries removed, weighed and fixed in 4% paraformaldehyde and stored 
refrigerated overnight after which they were put into 70% alcohol. Histological processing, follicular 
classification, enumeration and health status assessment were undertaken as previously described 
(Caldwell, Middleton et al. 2014).  
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For the present study, paraffin-wax embedded ovarian tissue from the DHT-induced PCOS mice and 
control mice will be sectioned at 4 μm in thickness and mounted onto glass slides, then dried overnight 
in a 370C incubator. These slides will be posted to Melbourne (RMIT University, Plenty Rd, Bundoora, 
VIC) for immunohistochemical staining for the following fibrinolytic/proteolytic markers: 
plasminogen, plasmin, tPA and uPA and inhibitor PAI-1. 
 
At RMIT, the glass slides will be stored securely prior to IHC testing. The antibodies used for IHC will 
be of monoclonal or polyclonal specificity, raised in rabbits and directed towards the 
fibrinolytic/proteolytic markers and inhibitor of interest. We will use Polymer based-IHC for 
immunohistochemical detection of PAI-1, tPA, uPA, plasmin and plasminogen of sectioned tissue in 
both control and PCOS mice (at various stages of the estrous cycle in PCOS mice and at the diestrus 
stage of the cycle in control mice). IHC will be performed on mice tissues know to contain PAI-1, tPA, 
uPA, plasmin and plasminogen (positive control tissues). A negative control will also be tested with 
each marker by omitting to add the primary antibody in the immunohistochemical procedure. 
 
PCOS and control sections will be stained simultaneously for each marker in order to avoid variability 
due to staining techniques. Sections will then be examined microscopically (Leica DMD 108) and 
photographed (under x100, x400 & x1000 magnification) with a digital camera (Leica). All images will 
be processed at the same time. Sections/images will be examined and characterized by three operators 
(Dr Dodie Pouniotis, A/Prof Ian Darby, Genia Burchall), blinded to the type of tissue (PCOS or 
control) viewed. Digital image analysis and processing of each photograph may be performed (if 
required). 
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Primary outcome measures 
 
Our main focus of this study is to assess the expression of the fibrinolytic/proteolytic markers 
plasminogen, plasmin, tPA and uPA and inhibitor PAI-1 within the PCOS and control mouse ovaries.  
 
PAI-1: PAI-1 primary antibody (rabbit polyclonal) from ABCAM (ab28207) can be used in paraffin 
embedded sections (IHC-P). The antibody will initially be tested in a positive control (in mouse lung 
and/or carotid know to contain PAI-1) according to the manufacturer’s instructions and on a negative 
control (also in mouse lung and/or carotid) with the primary antibody omitted.  
 
tPA:tPA primary antibody (rabbit polyclonal) from ABCAM (ab28208) can be used in paraffin 
embedded sections (IHC-P). As per the protocol stated for PAI-1 above, positive and negative controls 
will be tested for tPA (in mouse normal kidney tissue know to contain tPA). 
 
uPA:uPA primary antibody (rabbit monoclonal) from ABCAM (ab133563) can be used in paraffin 
embedded sections (IHC-P). As per the protocol stated for PAI-1 above, positive and negative controls 
will be tested for uPA (in mouse normal kidney tissue know to contain uPA).  
 
After confirmation that the antibodies for PAI-1, tPA and uPA have stained the positive control tissue 
appropriately (with no/scant background staining) and no staining observed in the negative control 
tissues, the antibodies will be used on the ovarian mouse PCOS and control tissue slides (received from 
Dr K Walters). Images of the slides will be taken using a digital camera. 
 
Plasminogen: Plasminogen primary antibody (rabbit polyclonal) from NOVUS (NB300-544) has been 
tested and shown to work in immunocytochemical (ICC) staining and therefore likely to also work in 
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IHC however this will need to be demonstrated/proven before testing on the PCOS and control ovarian 
tissue. As per the protocol stated for PAI-1 above, positive and negative controls will be tested for 
plasminogen (on mouse liver and/or adrenal gland known to contain plasminogen). After confirmation 
that the antibody has stained the positive control tissue appropriately (with no/minimal background 
staining) and no staining observed in the negative control tissue, the antibody will be tested (via IHC-P) 
on the ovarian mouse PCOS and control tissue slides received from Dr K Walters on one slide only 
(from each control and PCOS tissue). Images of slides will be taken with a digital camera. Further 
ovarian mouse PCOS and control tissue slides will be stained after initial/preliminary testing/staining. 
Plasminogen primary antibody (rabbit polyclonal) NB300-544 is specific for plasminogen and will not 
recognise plasmin. 
 
Plasminogen/Plasmin: Plasminogen/Plasmin primary antibody (rabbit polyclonal) from NOVUS 
(NBP2-19859) has been tested and shown also to work in ICC and therefore likely to also work in IHC 
however this will need to be demonstrated/proven before testing on the PCOS and control ovarian 
tissue. Testing/confirmation procedures will be as for that indicated for the plasminogen antibody 
above (NB300-544). Images of all slides will be taken with a digital camera. Plasminogen primary 
antibody (rabbit polyclonal) NBP2-19859 will recognise both plasminogen and plasmin.  
 
Significance of project 
This will be the first study that we are aware of that comprehensively evaluates the 
fibrinolytic/proteolytic system in the PCOS ovary. We will compare the expression of these markers 
between control and PCOS ovaries to observe what effect these may have on the latter. Outcomes from 
this study will support further research to be undertaken in this area as well as potentially lead to 
research into treatment modalities for overcoming the anovulation noted in many/most women with 
PCOS. As PCOS is the leading cause of anovulatory infertility in women in many countries, research 
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into this area could potentially provide significant breakthrough in the fertility treatment options for 
women with PCOS. Correlations between hormonal and metabolic markers with fibrinolytic markers in 
the ovary may also inform potential mechanisms of action in the anovulation process, follicular 
development and ovarian architecture in the PCOS ovary in this very complex and common disorder.  
 
Expected outputs 
It is expected this work will yield at least one journal publication and several conference abstracts. 
Outputs will include: 
- At least one manuscript and two or more conference (national and international) oral 
presentations and posters on the Fibrinolytic/Proteolytic Markers (plasminogen, 
plasmin, tPA & uPA) and inhibitors (PAI-1) in the PCOS Ovary 
Authorship will be decided according to the guidelines set out in the “Authorship and funding” 
section below. 
 
Ethics approval 
Ethics approval for the original study carried out on the control and PCOS mice in question has 
already been sought (by Dr Kirsty Walters, University of New South Wales) and approved by The 
Sydney Local Health District Animal Welfare Committee (as being within NHMRC guidelines for 
animal experimentation). The trial has been registered on clinicaltrials.gov and the Australian New 
Zealand Clinical Trials Register.   
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Statistical analyses plan 
Statistical analysis will not be required for this study.  
Intellectual property 
It will be acknowledged that this work was completed in an intellectual collaboration between the 
School of Health and Biomedical Sciences, RMIT University, Monash Centre for Health Research 
and Implementation (MCHRI), Monash University, ANZAC Research Institute, University of 
Sydney and the Robinson Research Institute, University of Adelaide.  All intellectual property for 
this project is managed by the School of Health and Biomedical Sciences.  
The investigator roles are as follows: 
x Assoc Prof Terrence Piva (CIA) – School of Health & Biomedical Sciences, RMIT University 
- Contribution to the design of the project 
- Principal supervisor of PhD student (Genia Burchall) 
- Reviewing manuscript (for publication) 
 
x Mrs Genia Burchall (CIB) – School of Health & Biomedical Sciences, RMIT University 
- Designing the original project and adjusting this based on feedback provided by other 
collaborators on the project 
- Training in IHC techniques and IHC testing of all control and test tissues of all markers of 
interest (as specified above) 
- Data analysis  
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- Writing the first draft (and all subsequent drafts) of the manuscript (following feedback 
received) 
- Writing and presenting outcomes of study at conferences (oral presentations and posters) 
 
x Prof Helena Teede (CIC) – MCHRI, SPHPM, Monash University 
- Contribution to the design of the project 
- Co-supervisor of PhD student (Genia Burchall) 
- Reviewing manuscript (for publication) 
 
x Assoc Prof Ian Darby – School of Health & Biomedical Sciences, RMIT University 
- Contribution to the design of the project 
- Training of PhD student (Genia Burchall) in IHC techniques 
- Reviewing manuscript (for publication) 
 
x Dr Kirsty Walters – ANZAC Research Institute, University of Sydney 
- Contribution to the design of the project 
- Provision of PCOS and control mice ovarian tissues 
- Embedding (paraffin) and cutting into sections PCOS and control mice ovarian samples, then 
placing on slides and posting to Melbourne 
- Reviewing manuscript (for publication) 
 
x Prof Ray Rogers – Robinson Research Institute, University of Adelaide 
- Contribution to the design of the project 
- Reviewing manuscript (for publication) 
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Authorship and funding 
Funding for this project will be obtained from The Helen MacPherson Smith Trust Grant, and  
the School of Health and Biomedical Sciences (RMIT). Publications costs as well as costs 
associated with travel to conferences will be covered by the School of Graduate Research, 
RMIT University. Authorship will be based on intellectual contribution throughout the project, 
including analysis and interpretation, and manuscript preparation. All CIs will be included as 
co-authors on all outputs and other team members will be included on publications for which 
they have made a significant contribution. CIA Piva will be last author on output (manuscript), 
unless otherwise agreed upon by the CIs. The first author of the article will be CIB Burchall 
(makes the largest contribution to data analysis and manuscript preparation). Those who are 
engaged in the project but not meeting authorship requirements will be acknowledged in the 
manuscript/s. The outcomes of the collaboration are anticipated to be presented at both national 
and international meetings.   
 
Agreement and signatures 
We the researchers agree to work collaboratively and collegially and in good faith, and to abide 
by the terms stated in this agreement/memorandum:    
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